<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Management in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Management in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Management in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jaime G Deville, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eunkyung Song, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Ouellette, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H490220817"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Starting in late 2019, a novel coronavirus rapidly spread throughout the world, resulting in a global pandemic. The virus was designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the illness it caused coronavirus disease 2019 (COVID-19). The clinical spectrum of COVID-19 ranges from asymptomatic infection to mild respiratory tract symptoms to severe pneumonia with acute respiratory distress syndrome and multiorgan dysfunction.</p><p>Understanding of COVID-19 is evolving. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2FWHO-2019-nCoV-clinical-2021-2&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7uTgB8glbKNm0sPo4%2B8z2sxDDRq3RsxdDePKvJAZemGlr4SIch0ubsJXu0hRi5XFo%3D&amp;TOPIC_ID=128389" target="_blank">World Health Organization</a>, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-nCoV%2Fhcp%2Findex.html&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLETVYV9fJcW0p5%2FSZ3txP%2BHM5kLLHknys0%2FgSZyXivAUDtgQTTNyLN5lgxmxNs%2B4jK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=128389" target="_blank">United States Centers for Disease Control and Prevention</a>, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2F&amp;token=Rk4xBkzE1SGKS%2Ff2rhl9kQmuTkA5VPYaYYgW%2BkL8Vtaoio6E54z5hw7UfvwH3kkfQcoU19a4ked5Vtez8asrRyoIjN8BVzblDISl2B9kdmQ%3D&amp;TOPIC_ID=128389" target="_blank">American Academy of Pediatrics</a>, and other expert groups provide ongoing guidance for evaluation, management, and prevention. Links to these and other related society guidelines are found elsewhere. (See <a class="local">'Society guideline links'</a> below.)</p><p>This topic will discuss the management of COVID-19 in children. The epidemiology and clinical features of COVID-19 that are specific to children, multisystem inflammatory syndrome in children, and COVID-19 in pregnancy are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129614.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127535.html" rel="external">"COVID-19: Overview of pregnancy issues"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/134827.html" rel="external">"COVID-19: Antepartum care of pregnant patients with symptomatic infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129846.html" rel="external">"COVID-19: Intrapartum and postpartum issues"</a>.)</p><p></p><p>In addition, please refer to our <a class="external" href="/landing/covid19?search=covid 19" target="_blank">COVID-19 homepage</a> to view the complete list of UpToDate COVID-19 topics.</p><p class="headingAnchor" id="H2364166907"><span class="h1">ASSESSMENT OF SEVERITY</span><span class="headingEndMark"> — </span>We use the definitions of severity provided in the multicenter interim guidance on the use of antivirals for children with COVID-19  (<a class="graphic graphic_table graphicRef139079" href="/z/d/graphic/139079.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild or moderate disease – No new or increased supplemental oxygen requirement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe disease – New requirement for supplemental oxygen or increased requirement from baseline without new or increased need for ventilatory support (noninvasive or invasive)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Critical disease – New or increased need for noninvasive or invasive mechanical ventilation, sepsis, multiorgan failure, or rapidly worsening clinical trajectory</p><p></p><p class="headingAnchor" id="H3424747904"><span class="h1">GENERAL MANAGEMENT CONSIDERATIONS</span></p><p class="headingAnchor" id="H2646921871"><span class="h2">Management of chronic medications</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAIDs</strong> – Nonsteroidal anti-inflammatory drugs (NSAIDs) that are used chronically for other conditions may be continued unless there are other reasons for discontinuation (eg, gastrointestinal bleeding, renal injury) [<a href="#rid2">2-4</a>]. Despite initial concerns about the safety of NSAIDs in patients with COVID-19 [<a href="#rid5">5,6</a>], in a meta-analysis of 11 observational studies (&gt;683,000 participants), exposure to NSAIDs was not associated with increased risk of SARS-CoV-2 infection, severe/critical COVID-19 disease, or all-cause mortality [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthma medications</strong> – Considerations related to the safety of glucocorticoid and nebulized medications for children with asthma are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management", section on 'Advice related to COVID-19 pandemic'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACE inhibitors and angiotensin receptor blockers</strong> – Children receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) should continue treatment with these agents if there is no other reason for discontinuation (eg, hypotension, acute kidney injury) [<a href="#rid8">8</a>]. This approach is supported by multiple guideline panels [<a href="#rid9">9-13</a>].</p><p></p><p class="bulletIndent1">Although there has been speculation that patients with COVID-19 who are receiving ACE inhibitors or ARBs may be at increased risk for adverse outcomes, the hypothesis is not supported by findings from observational studies. (See  <a class="medical medical_review" href="/z/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'Renin angiotensin system inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppressive therapy</strong> – For children receiving immunosuppressive therapy, we discuss the benefits and risks of reducing immunosuppressive therapy with the prescribing specialist (eg, oncologist, transplant clinician, rheumatologist, gastroenterologist). Although the relationship between immune compromise and severe COVID-19 disease has not been well established in children [<a href="#rid14">14,15</a>], management of viral infections in immunocompromised hosts typically includes reduction of baseline immunosuppression, if reduction is possible [<a href="#rid16">16,17</a>]. Information about adjusting immunosuppressive therapy for specific conditions is presented separately. (See  <a class="medical medical_review" href="/z/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Adjusting immunosuppression'</a>.)</p><p></p><p class="headingAnchor" id="H1096670095"><span class="h2">Management of multisystem inflammatory syndrome in children</span><span class="headingEndMark"> — </span>The management of multisystem inflammatory syndrome in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129614.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome", section on 'Management'</a>.)</p><p class="headingAnchor" id="H2022111647"><span class="h2">Management of possible coinfection with influenza</span><span class="headingEndMark"> — </span>Recommendations for antiviral therapy for influenza infection in children are unchanged during the COVID-19 pandemic [<a href="#rid2">2</a>]. If indicated, antiviral therapy for influenza can be initiated while awaiting laboratory results. If initiated, antiviral therapy can be discontinued when influenza has been excluded through molecular testing. Antiviral therapy and laboratory testing for influenza are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">"Seasonal influenza in children: Management", section on 'Antiviral therapy'</a> and  <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">"Seasonal influenza in children: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H1932000153"><span class="h1">INDICATIONS FOR HOSPITALIZATION</span><span class="headingEndMark"> — </span>Indications for hospitalization in children with COVID-19 include:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe or critical lower respiratory tract disease  (<a class="graphic graphic_table graphicRef139079" href="/z/d/graphic/139079.html" rel="external">table 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsevere disease with underlying conditions that increase the risk of severe disease (eg, immune compromise)</p><p class="bulletIndent1"><span class="glyph">●</span>Fever in infant younger than 30 days</p><p></p><p class="headingAnchor" id="H1920444033"><span class="h1">MANAGEMENT OF HOSPITALIZED CHILDREN</span></p><p class="headingAnchor" id="H4177283456"><span class="h2">Supportive care for all patients</span><span class="headingEndMark"> — </span>We provide supportive care for all pediatric patients with COVID-19 as recommended by various national committees [<a href="#rid1">1,2,18</a>]. Supportive care is the mainstay of therapy for patients with severe or critical COVID-19 [<a href="#rid19">19</a>]. Most children with COVID-19 improve with supportive care, even those with severe disease [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children", section on 'Society guideline links'</a>.)</p><p>Routine supportive care measures include:</p><p class="bulletIndent1"><span class="glyph">●</span>Provision of respiratory support, including supplemental oxygen and ventilatory support (noninvasive or invasive); respiratory status may change suddenly after approximately one week of symptoms [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/6393.html" rel="external">"Initial assessment and stabilization of children with respiratory or circulatory compromise"</a> and  <a class="medical medical_review" href="/z/d/html/6316.html" rel="external">"Technique of emergency endotracheal intubation in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provision of fluid and electrolyte support. (See  <a class="medical medical_review" href="/z/d/html/5065.html" rel="external">"Fluid and electrolyte therapy in newborns"</a> and  <a class="medical medical_review" href="/z/d/html/6142.html" rel="external">"Clinical assessment of hypovolemia (dehydration) in children"</a> and  <a class="medical medical_review" href="/z/d/html/6103.html" rel="external">"Treatment of hypovolemia (dehydration) in children in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provision of empiric antibiotics as indicated for community-acquired or health care-associated pneumonia; continuation of empiric antibiotics should be determined by cultures and other microbial tests and clinical condition. Bacterial coinfections at the time of presentation appear to be infrequent [<a href="#rid21">21,22</a>]. (See  <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">"Pneumonia in children: Inpatient treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring for cytokine release syndrome by monitoring blood pressure for hypotension, oxygen saturation for worsening hypoxemia, and biomarkers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We obtain baseline C-reactive protein (CRP), D-dimer, ferritin, lactate dehydrogenase (LDH), and interleukin-6 (IL-6).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We monitor CRP, D-dimer, ferritin, and LDH two or three times per week or if there is concern for worsening disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provision of thromboprophylaxis – Interventions to reduce the risk of venous thromboembolism (VTE) may be warranted for children hospitalized with COVID-19 [<a href="#rid23">23,24</a>].</p><p></p><p class="bulletIndent1">We encourage nonpharmacologic strategies for VTE prophylaxis (eg, intermittent pneumatic compression devices [size permitting] and early mobilization).</p><p></p><p class="bulletIndent1">For hospitalized children without multisystem inflammatory syndrome in children (MIS-C), we make decisions about pharmacologic VTE prophylaxis on a case-by-case basis, considering other VTE risk factors  (<a class="graphic graphic_table graphicRef122844" href="/z/d/graphic/122844.html" rel="external">table 2</a>) and the child's risk of bleeding. The pharmacologic approach to VTE prophylaxis in hospitalized children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Approach to VTE prophylaxis'</a>.)</p><p></p><p class="bulletIndent1">The risk of thrombotic complications in children with COVID-19 has not been well defined. In two multicenter cohort studies (one from the United States, the other from Spain, each including &gt;400 patients), between 1 and 2 percent of children hospitalized with SARS-CoV-2 (excluding children with MIS-C) had thrombotic complications (eg, deep vein thrombosis of the upper or lower extremity, pulmonary embolism, intracardiac thrombosis, cerebral sinovenous thrombosis) [<a href="#rid25">25,26</a>]. Most of the patients with thrombotic complications were ≥12 years of age; many had risk factors for thrombosis, and some received thromboprophylaxis before developing thrombosis. Underlying risk factors for thrombosis included cancer, obesity, critical illness, and central venous catheter. The usefulness of D-dimer &gt;5 times the upper limit of normal as a predictor of thrombosis was inconsistent.</p><p></p><p class="bulletIndent1">The risk of VTE in children with MIS-C and VTE prophylaxis for children with MIS-C are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129614.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome", section on 'Antithrombotic therapy'</a>.)</p><p></p><p class="headingAnchor" id="H4205110861"><span class="h2">SARS-CoV-2 antiviral therapy for select patients</span><span class="headingEndMark"> — </span>Given the lack of data from controlled trials supporting the efficacy of antiviral agents for the treatment of COVID-19 in children [<a href="#rid27">27</a>], we agree with recommendations from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fjpids%2Farticle%2F10%2F1%2F34%2F5904884&amp;token=djYKyj9M2WrCg90ff%2F0Y78uMNz3h7KRs0ax7Aq%2BgGcAzWJa2Yzt5jHZp%2FOlUhxNOJ0wbiifkiJnVqWfcvDvmaw%3D%3D&amp;TOPIC_ID=128389" target="_blank">multicenter interim guidance on the use of antiviral agents for children with COVID-19</a> and other experts that antiviral therapy should be considered on a case-by-case basis and preferably occur in the context of a clinical trial, if a clinical trial is available [<a href="#rid1">1,28</a>]. Information about ongoing clinical trials is available from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=128389" target="_blank">ClinicalTrials.gov</a>.</p><p>Antiviral therapy for COVID-19 should be reserved for children with documented SARS-CoV-2 infection if testing is available [<a href="#rid1">1</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential indications</strong> – Decisions to use antiviral therapy should be individualized according to disease severity, clinical trajectory, existing evidence of effectiveness, and underlying conditions that may increase the risk for progression. Studies of the effectiveness and safety of antiviral therapy have predominantly been performed in adults with severe lower respiratory tract disease [<a href="#rid29">29-31</a>]; these studies are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Specific treatments'</a>.)</p><p></p><p class="bulletIndent1">Despite the unproven benefits, we suggest antiviral therapy for children with documented severe or critical COVID-19. Antiviral therapy also may be warranted for children with mild or moderate disease and an underlying condition that increases or may increase the risk of severe disease (eg, medical complexity, congenital heart disease, among others). (See  <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children", section on 'Risk factors for severe disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of agent/regimen</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Remdesivir</strong> – <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">Remdesivir</a> is a prodrug of a nucleotide analog that inhibits ribonucleic acid (RNA)-dependent RNA polymerase and has activity against coronaviruses [<a href="#rid32">32-35</a>].</p><p></p><p class="bulletIndent2">When a decision is made to use antiviral therapy in a child who cannot be enrolled in a clinical trial, we suggest <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> rather than other antiviral agents, in agreement with the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fjpids%2Farticle%2F10%2F1%2F34%2F5904884&amp;token=djYKyj9M2WrCg90ff%2F0Y78uMNz3h7KRs0ax7Aq%2BgGcAzWJa2Yzt5jHZp%2FOlUhxNOJ0wbiifkiJnVqWfcvDvmaw%3D%3D&amp;TOPIC_ID=128389" target="_blank">multicenter panel</a> [<a href="#rid1">1</a>]. Although data regarding the benefits of remdesivir for children with COVID-19 are limited, it is preferred to other antiviral agents because data from randomized and observational studies in adult patients suggest that it may reduce time to recovery (particularly in patients who are not critically ill); it appears to be well tolerated [<a href="#rid1">1,36-45</a>]. Studies of remdesivir in adult patients with COVID-19 are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Remdesivir'</a>.)</p><p></p><p class="bulletIndent2">When the supply of <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> is limited, it should be prioritized for patients who do not require ventilation (invasive or noninvasive); the benefits for those who require ventilation are uncertain [<a href="#rid2">2,46</a>]. (See <a class="local">'Assessment of severity'</a> above.)</p><p></p><p class="bulletIndent2">The optimal role of <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> in patients with COVID-19 remains uncertain, and some experts suggest not using it in hospitalized patients [<a href="#rid47">47,48</a>]. In the United States, remdesivir has been approved by the US Food and Drug Administration (FDA) for the treatment of both hospitalized and nonhospitalized COVID-19 in adults and children ≥28 days of age who weigh ≥3 kg [<a href="#rid49">49,50</a>].</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">Remdesivir</a> is dosed according to weight as follows [<a href="#rid50">50</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>≥3 to &lt;40 kg – 5 mg/kg intravenous (IV) loading dose on day 1, followed by 2.5 mg/kg IV every 24 hours</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>≥40 kg – 200 mg IV loading dose on day 1, followed by 100 mg IV every 24 hours</p><p></p><p class="bulletIndent2">The usual duration of therapy is up to 5 days for children with severe disease; for children with critical disease who are not improving after 5 days, the duration may be extended to up to 10 days [<a href="#rid1">1,51</a>].</p><p></p><p class="bulletIndent2">Reported adverse effects of <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> include nausea, vomiting, and transaminase elevations. In a review of compassionate use of remdesivir in 77 children hospitalized with severe SARS-CoV-2 infection, 33 percent had adverse events and 16 percent had serious adverse events, most of which were related to COVID-19 or underlying conditions (eg, hypoxia, acute respiratory failure, recurrence of acute lymphocytic leukemia) [<a href="#rid52">52</a>]. The only adverse events to occur in more than one patient were elevation of serum aminotransferases (in nine) and anemia (in two). Cases of bradycardia attributable to remdesivir have also been reported [<a href="#rid53">53-56</a>].</p><p></p><p class="bulletIndent2">Licensure of <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> in hospitalized children &lt;12 years of age was supported by trials in adult patients and a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT04431453&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSwjDhjjcHHWHmVYzJmQHXMpOkStDY9Q73a8mKxMBTnCMw%3D%3D&amp;TOPIC_ID=128389" target="_blank">single-arm, open-label study</a> in 53 children ≥28 days with confirmed mild, moderate, or severe SARS-CoV-2 infection (41 were &lt;12 years of age), in which remdesivir was associated with improvement in clinical status [<a href="#rid49">49,50,57</a>]. Study participants were unvaccinated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Baricitinib</strong> – <a class="drug drug_pediatric" data-topicid="130212" href="/z/d/drug information/130212.html" rel="external">Baricitinib</a> is approved by the FDA for the treatment of adult patients who are hospitalized with COVID-19 and require oxygen or ventilatory support or extracorporeal membrane oxygenation [<a href="#rid58">58</a>]. For children age ≥2 to 18 years, it has an emergency use authorization (EUA) [<a href="#rid59">59</a>]. However, there is limited information about the benefits and risks of baricitinib in children with COVID-19 [<a href="#rid2">2</a>]. It should ideally be used in the context of a clinical trial.</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="130212" href="/z/d/drug information/130212.html" rel="external">Baricitinib</a> is a Janus kinase inhibitor used for the treatment of rheumatoid arthritis. In addition to its immunomodulatory effects, it is thought to have antiviral effects through interference with viral entry. Baricitinib may provide a mortality benefit for select patients, including those already receiving glucocorticoids. In studies in patients ≥18 years of age, baricitinib appeared to reduce mortality and the combination of baricitinib and <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> appeared to modestly improve the time to recovery without increased rates of infection, VTE, or other adverse events [<a href="#rid59">59-62</a>]. Studies of baricitinib in adult patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Baricitinib and JAK inhibitors'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hydroxychloroquine</strong><strong> and </strong><strong>chloroquine</strong><strong> </strong>– We recommend not using <a class="drug drug_pediatric" data-topicid="13366" href="/z/d/drug information/13366.html" rel="external">hydroxychloroquine</a> or <a class="drug drug_pediatric" data-topicid="13147" href="/z/d/drug information/13147.html" rel="external">chloroquine</a> for the treatment of COVID-19 in children. It has not been proven effective and is associated with severe adverse reactions [<a href="#rid63">63-67</a>]. Hydroxychloroquine is not licensed for this indication, and its EUA for the treatment of COVID-19 in the United States has been revoked [<a href="#rid68">68,69</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lopinavir-ritonavir</strong> – We do not recommend routine use of <a class="drug drug_pediatric" data-topicid="12562" href="/z/d/drug information/12562.html" rel="external">lopinavir-ritonavir</a> given the absence of efficacy and unfavorable pharmacodynamics [<a href="#rid18">18,30,31,70,71</a>]. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Others'</a>.)</p><p></p><p class="headingAnchor" id="H1067533135"><span class="h2">Individualized adjunctive therapy</span></p><p class="headingAnchor" id="H3307255597"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>We make decisions about the use of glucocorticoids for immune-mediated complications of COVID-19 on a case-by-case basis according to disease severity [<a href="#rid72">72</a>]. Although glucocorticoids have been associated with decreased mortality in adult patients [<a href="#rid73">73-75</a>], trials in children are ongoing and the benefits and risks are uncertain. Pending results of these trials, administration of glucocorticoids ideally should occur in the context of a clinical trial. Information about ongoing clinical trials is available from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=128389" target="_blank">ClinicalTrials.gov</a>.</p><p>For select children with severe or critical COVID-19 who cannot participate in a clinical trial (ie, those who require mechanical ventilation or those who require supplemental oxygen and have risk factors for disease progression), low-dose glucocorticoids may be warranted at the time of admission [<a href="#rid72">72,76</a>]; the duration of therapy is up to 10 days or until discharge, whichever is shorter. In an observational study in adults, extending glucocorticoid therapy beyond discharge was not associated with decreased rates of readmission or death [<a href="#rid77">77</a>].</p><p>Low-dose glucocorticoid regimens include one of the following (<a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> is preferred if available) [<a href="#rid2">2,76,78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">Dexamethasone</a> 0.15 mg/kg orally, IV, or nasogastrically (NG) once daily (maximum dose 6 mg)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12723" href="/z/d/drug information/12723.html" rel="external">Prednisolone</a> 1 mg/kg orally or NG once daily (maximum dose 40 mg)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12601" href="/z/d/drug information/12601.html" rel="external">Methylprednisolone</a> 0.8 mg/kg IV once daily (maximum dose 32 mg)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">Hydrocortisone</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For neonates (&lt;1 month of age) – 0.5 mg/kg IV every 12 hours for 7 days followed by 0.5 mg/kg IV once daily for 3 days</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children ≥1 month – 1.3 mg/kg IV every 8 hours (maximum dose 50 mg; maximum total daily dose 150 mg)</p><p></p><p>The use of glucocorticoids is supported by randomized trials comparing glucocorticoids with placebo or usual care, predominantly in adult patients with severe or critical COVID-19. In a meta-analysis of seven randomized trials, in a total of 1703 critically ill patients [<a href="#rid79">79-82</a>], glucocorticoids reduced 28-day all-cause mortality (33 versus 41 percent, odds ratio 0.66, 95% CI 0.53-0.82) without increased serious adverse events [<a href="#rid73">73</a>]. The results were similar with <a class="drug drug_pediatric" data-topicid="13214" href="/z/d/drug information/13214.html" rel="external">dexamethasone</a> or <a class="drug drug_pediatric" data-topicid="13361" href="/z/d/drug information/13361.html" rel="external">hydrocortisone</a>. Another meta-analysis of randomized trials comparing glucocorticoids with standard care irrespective of disease severity concluded that glucocorticoids probably reduce all-cause mortality at a median of 28 days (24.5 versus 27.5 percent; risk ratio 0.89, 95% CI 0.80-1.00) and may increase ventilator-free days [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'</a>.)</p><p>Although the WHO strongly recommends systemic glucocorticoids for patients with severe or critical COVID-19, they acknowledge that the applicability of the recommendation for children is uncertain because children were underrepresented in the clinical trials supporting benefit [<a href="#rid76">76</a>]. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H1397166673"><span class="h3">Glucocorticoids plus tocilizumab</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">Tocilizumab</a> is a monoclonal antibody that reduces inflammation by blocking the IL-6 receptor. It is used in the management of several rheumatologic conditions in children and adults (eg, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome).</p><p><a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">Tocilizumab</a> is approved for the treatment of COVID-19 in hospitalized adult patients who are receiving systemic glucocorticoids and require supplemental oxygenation, mechanical ventilation (noninvasive or invasive), or extracorporeal membrane oxygenation [<a href="#rid84">84</a>]. It has <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F150321%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPE%2FpBaHqq74b0Y7DJ8V7x1L3Bk7bsMIXTX2fTbYIO6DYj1%2B1RaSbgMbyw0rSukZgXg%3D%3D&amp;TOPIC_ID=128389" target="_blank">EUA</a> for treatment of such hospitalized children ≥2 years of age [<a href="#rid85">85</a>]. However, there is limited information about the benefits and risks of tocilizumab in children with COVID-19 [<a href="#rid2">2,70,86</a>]. It should ideally be used in the context of a clinical trial.</p><p><a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">Tocilizumab</a> is dosed according to patient weight [<a href="#rid85">85</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>&lt;30 kg – 12 mg/kg IV in a single 60-minute infusion</p><p class="bulletIndent1"><span class="glyph">●</span>≥30 kg – 8 mg/kg IV in a single 60-minute infusion (maximum 800 mg per infusion)</p><p></p><p><a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">Tocilizumab</a> may be repeated once ≥8 hours after the initial infusion if clinical signs or symptoms worsen or do not improve after the first dose.</p><p><a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">Tocilizumab</a> should be avoided in individuals with hypersensitivity to tocilizumab, uncontrolled serious infections other than COVID-19, absolute neutrophil count &lt;1000 cells/microL, platelet counts &lt;50,000/microL, alanine aminotransferase &gt;5 times the upper limit of normal, or elevated risk for gastrointestinal perforation [<a href="#rid2">2,85</a>]. Tocilizumab should be used with caution in immunocompromised individuals as very few were included in randomized trials. Administration of live vaccines (eg, measles, mumps, rubella, varicella) should be deferred for at least two weeks after the final infusion of tocilizumab [<a href="#rid87">87</a>]; some experts would wait at least four weeks before administration of live vaccines.</p><p><a class="drug drug_pediatric" data-topicid="88097" href="/z/d/drug information/88097.html" rel="external">Tocilizumab</a> may reduce progression to mechanical ventilation, duration of hospitality, and mortality in adults with COVID-19, but the findings are inconsistent. Studies describing the use of tocilizumab in adult patients with COVID-19 are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'IL-6 pathway inhibitors (eg, tocilizumab)'</a>.)</p><p>In adult patients with COVID-19, the most commonly reported adverse reactions were constipation, diarrhea, nausea, anxiety, insomnia, hypertension, and superinfection [<a href="#rid85">85,88</a>].</p><p class="headingAnchor" id="H4252601152"><span class="h3">Other adjunctive therapies</span><span class="headingEndMark"> — </span>We make decisions about the use of other adjunctive therapies for immune-mediated complications of COVID-19 on a case-by-case basis according to disease severity and in consultation with specialty services as indicated (eg, rheumatology, infectious diseases) [<a href="#rid72">72</a>]. The immune response to SARS-CoV-2 is variable and may include marked systemic inflammation and/or immune suppression [<a href="#rid89">89</a>].</p><p>We do not routinely use other immune modulators (<a class="drug drug_pediatric" data-topicid="13384" href="/z/d/drug information/13384.html" rel="external">interferon alfa-2b</a>, interferon-beta 1b, convalescent plasma from recovered COVID-19 patients) in the treatment of children hospitalized with COVID-19, except in the context of a clinical trial [<a href="#rid72">72</a>]. The benefits and risks are uncertain [<a href="#rid2">2,72,75,90-98</a>]. The use of immune-modifying therapies in children with multisystem inflammatory syndrome and the use of immune-modifying therapies in adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129614.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome", section on 'Immunomodulatory therapy'</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'COVID-19-specific therapy'</a>.)</p><p>Information about ongoing clinical trials is available from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=128389" target="_blank">ClinicalTrials.gov</a>.</p><p>Although there are no available data on the use of <a class="drug drug_pediatric" data-topicid="12883" href="/z/d/drug information/12883.html" rel="external">vitamin A</a> for the treatment of COVID-19, vitamin A has long been used as an adjunctive therapy in the treatment of measles, and its use has been associated with decreased morbidity and mortality from measles-associated pneumonia [<a href="#rid99">99</a>]. Vitamin A deficiency may be associated with impairment of humoral and cell-mediated immunity, and even mild vitamin A deficiency may lead to increased morbidity from measles and other viral respiratory infections [<a href="#rid99">99</a>]. (See  <a class="medical medical_review" href="/z/d/html/3021.html" rel="external">"Measles: Clinical manifestations, diagnosis, treatment, and prevention", section on 'Vitamin A'</a>.)</p><p class="headingAnchor" id="H4176123957"><span class="h1">OUTPATIENT MANAGEMENT</span><span class="headingEndMark"> — </span>Children with documented or suspected COVID-19 and mild symptoms (eg, fever, cough, pharyngitis, other respiratory symptoms) generally can be managed at home unless they have a chronic condition that increases their risk of severe disease.</p><p>Outpatient management of children with SARS-CoV-2 infection is focused on prompt provision of outpatient therapy for select patients at high risk of progression to severe disease, provision of symptomatic and supportive care, monitoring for clinical deterioration, and prevention of transmission to others (isolation).</p><p>The Centers for Disease Control and Prevention (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fif-you-are-sick%2Findex.html%23%3A%7E%3Atext%3DContact%2520a%2520healthcare%2520provider%2520right%2Cfew%2520days%2520to%2520be%2520effective&amp;token=Otj5%2BXBGO9DNYRUZT8OMyvL50C%2B33Tzsc%2FlaVHEgUxnXaBwdTZON9f9MCucbDLcSyxTV9kEicNOcvapLgqS4WQVANXhq%2Fo%2B7g27KRvHwHJQiQCHD3NhQCgnDy7Rh4Wd6GIm6KMKUWfQv%2Fqu%2FtLefCsYFYEAM466e1KQHaNYGHDTCBOojiKpUDQQHZpC03YQ%2B&amp;TOPIC_ID=128389" target="_blank">CDC</a>) and World Health Organization (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fhome-care-for-patients-with-suspected-novel-coronavirus-%28ncov%29-infection-presenting-with-mild-symptoms-and-management-of-contacts&amp;token=JuUD9LLbWAI%2FZfQMeccrsf4%2BXrNnpt%2F7JgqmfsdlOdSiE2FwmZQx5IYUDqkOxMAaFfjAAyKBFLZobbHKPzJm1dAlqnGMEC3CWm1Hi13n14BxWR1CYSGeFwiYOuYDX2xr66liAeECeQOJNnXK77xqKvlZFCExDwXxpuBlbv1Y%2FTqvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=128389" target="_blank">WHO</a>) provide additional guidance on what to do when someone is sick [<a href="#rid100">100,101</a>]. (See <a class="local">'Prevention of transmission'</a> below.)</p><p class="headingAnchor" id="H2158256345"><span class="h2">Outpatient therapy for select children</span></p><p class="headingAnchor" id="H4184839147"><span class="h3">Potential indications</span><span class="headingEndMark"> — </span>We consider outpatient therapy for children with mild-to-moderate COVID-19 disease who are at high risk for progression to severe disease on a case-by-case basis. Robust evidence associating specific underlying conditions with progression to severe illness in children is limited [<a href="#rid1">1,102</a>].</p><p>Potential indications for outpatient therapy in children include [<a href="#rid103">103,104</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One or more of multiple underlying conditions (eg, congenital heart disease/cardiovascular disease; genetic, neurologic, or metabolic condition)</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of vaccination against COVID-19</p><p class="bulletIndent1"><span class="glyph">●</span>Expected inadequate response to COVID-19 vaccine (eg, due to immunosuppressive disease or immunosuppressive therapies)</p><p class="bulletIndent1"><span class="glyph">●</span>Medical-related technologic dependence not related to COVID-19 (eg, tracheostomy positive pressure ventilation)</p><p class="bulletIndent1"><span class="glyph">●</span>Having obesity (body mass index ≥95<sup>th</sup> percentile for age and sex [males: (<a class="calc calc_professional" href="/z/d/html/13412.html" rel="external">calculator 1</a>), females: (<a class="calc calc_professional" href="/z/d/html/13415.html" rel="external">calculator 2</a>)])</p><p></p><p>Available outpatient therapies for children and adolescents with SARS-CoV-2 infection must be initiated within five to seven days of symptom onset, which requires that decisions about treatment be made soon as soon as possible after a positive test.</p><p class="headingAnchor" id="H650415500"><span class="h3">Choice of therapy</span><span class="headingEndMark"> — </span>When outpatient antiviral therapy is warranted for children with COVID-19, we suggest <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a> or intravenous (IV) <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> (depending on age, weight, and other factors) rather than other therapies  (<a class="graphic graphic_table graphicRef139078" href="/z/d/graphic/139078.html" rel="external">table 3</a>). <a class="drug drug_pediatric" data-topicid="134698" href="/z/d/drug information/134698.html" rel="external">Molnupiravir</a> is an alternative for patients ≥18 years of age if nirmatrelvir-ritonavir and remdesivir are unavailable or clinically inappropriate. Although there is limited information about the effectiveness of these interventions in children and adolescents, in randomized trials in nonhospitalized adults, they substantially reduced the risk of hospitalization. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Treatment with COVID-19-specific therapies'</a>.)</p><p>Administration of these agents is discussed below. (See <a class="local">'Antiviral therapies'</a> below.)</p><p>We choose among the suggested therapies on a case-by-case basis, considering the  (<a class="graphic graphic_table graphicRef139078" href="/z/d/graphic/139078.html" rel="external">table 3</a>) [<a href="#rid2">2,18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>SARS-CoV-2 variant/subvariant (if known) or the prevalence of circulating SARS-CoV-2 subvariants, which affects susceptibility  (<a class="graphic graphic_table graphicRef131216" href="/z/d/graphic/131216.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1">Given the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=128389" target="_blank">high frequency of circulation</a> of the Omicron (B.1.1.529) variant and the Omicron BA.2 subvariant throughout the United States, <a class="drug drug_pediatric" data-topicid="130800" href="/z/d/drug information/130800.html" rel="external">bamlanivimab-etesevimab</a>, <a class="drug drug_pediatric" data-topicid="130226" href="/z/d/drug information/130226.html" rel="external">casirivimab-imdevimab</a>, <a class="drug drug_pediatric" data-topicid="131734" href="/z/d/drug information/131734.html" rel="external">sotrovimab</a>, and <a class="drug drug_pediatric" data-topicid="134986" href="/z/d/drug information/134986.html" rel="external">bebtelovimab</a> are no longer authorized for use in the United States (including territories and jurisdictions) [<a href="#rid105">105-108</a>].</p><p></p><p class="bulletIndent1">In the United States, the regional prevalence of circulating variants is available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=128389" target="_blank">CDC</a> [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Local availability of therapies; limited supplies may warrant prioritization for those at highest risk of severe disease  (<a class="graphic graphic_table graphicRef134702" href="/z/d/graphic/134702.html" rel="external">table 5</a>) [<a href="#rid2">2,110</a>] (ie, unvaccinated children and children expected to have an inadequate vaccine response).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duration of symptoms; all of the available outpatient therapies should be initiated as soon as possible after positive SARS-CoV-2 test and within a specified time from symptom onset:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Five days for <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a> and <a class="drug drug_pediatric" data-topicid="134698" href="/z/d/drug information/134698.html" rel="external">molnupiravir</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Seven days for <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Feasibility of administering parenteral medications (eg, <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Feasibility of administering oral medications (eg, <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a> tablets cannot be chewed, broken, or crushed)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Child's age; the therapies are approved or authorized for particular age groups:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥28 days and weight ≥3 kg – <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">Remdesivir</a> (US Food and Drug Administration [FDA] approved)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥12 years and weight ≥ 40 kg – <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">Nirmatrelvir-ritonavir</a> (EUA)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥18 years – <a class="drug drug_pediatric" data-topicid="134698" href="/z/d/drug information/134698.html" rel="external">Molnupiravir</a> (EUA)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comorbidities and potential for drug-drug interactions (particularly with <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a>)</p><p></p><p class="headingAnchor" id="H887149839"><span class="h3">Antiviral therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nirmatrelvir-ritonavir</strong> — <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">Nirmatrelvir-ritonavir</a> is an oral protease inhibitor that prevents viral replication. It is expected to retain activity against Omicron (including subvariants), but data are limited [<a href="#rid2">2,111</a>].</p><p></p><p class="bulletIndent1">The FDA issued an <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F155050%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPIbMHcPXd5rIyY6xu0AU1A%2FoeHFimiKL03PZrDiPrCpREbrf7mm2Tbzuty%2BzQqYbKw%3D%3D&amp;TOPIC_ID=128389" target="_blank">EUA</a> for <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a> for the treatment of mild-to-moderate COVID-19 disease in adults and children who are ≥12 years of age and weigh ≥40 kg who are at high risk for progression to severe disease  (<a class="graphic graphic_table graphicRef127477" href="/z/d/graphic/127477.html" rel="external">table 6</a>) [<a href="#rid112">112</a>]. In randomized trials in adult outpatients, nirmatrelvir-ritonavir reduced the risk of hospitalization or death [<a href="#rid113">113-116</a>]. Data in children are limited [<a href="#rid117">117</a>]. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Nirmatrelvir-ritonavir as preferred therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing and dose</strong> – <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">Nirmatrelvir-ritonavir</a> should be initiated as soon as possible following COVID-19 diagnosis and within five days of symptom onset. The dose varies according to estimated glomerular filtration rate (eGFR) [<a href="#rid112">112</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>eGFR ≥60 mL/min (normal kidney function) – Nirmatrelvir 300 mg (two 150 mg tablets) and <a class="drug drug_pediatric" data-topicid="12970" href="/z/d/drug information/12970.html" rel="external">ritonavir</a> 100 mg taken together orally twice daily for five days</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>eGFR 30 to 59 mL/min (moderately reduced kidney function) – Nirmatrelvir 150 mg and <a class="drug drug_pediatric" data-topicid="12970" href="/z/d/drug information/12970.html" rel="external">ritonavir</a> 100 mg taken together orally twice daily for five days</p><p></p><p class="bulletIndent2">When prescribing <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a>, specify the dose for each active ingredient to avoid dosing errors and facilitate provision of the correct packaging configuration [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraindications and precautions </strong>– <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">Nirmatrelvir-ritonavir</a> is not recommended for patients with eGFR &lt;30 mL/min or for patients with severe hepatic impairment (Child-Pugh class C)  (<a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">table 7</a>).</p><p></p><p class="bulletIndent2"><a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">Nirmatrelvir-ritonavir</a> is a CYP3A inhibitor, and coadministration is contraindicated with drugs that are highly dependent upon CYP3A for clearance and in which an elevated level may be dangerous [<a href="#rid112">112</a>]. Coadministration is also contraindicated with potent CYP3A inducers, which may reduce levels of nirmatrelvir and/or <a class="drug drug_pediatric" data-topicid="12970" href="/z/d/drug information/12970.html" rel="external">ritonavir</a> and result in loss of efficacy or resistance.</p><p></p><p class="bulletIndent2">Specific interactions of <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a> with other medications may be determined using the <a class="external" href="/drug-interactions">Lexicomp drug interactions</a> tool (Lexi-Interact) included in UpToDate. The FDA provides a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F158165%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPEWXMUsrBHrxzLkxlcHJbfRutyegymwtmsIOb3uJgghbGFBMHJgu58aIztbJymOYqQ%3D%3D&amp;TOPIC_ID=128389" target="_blank">patient eligibility screening checklist and guidance for managing drug interactions</a> with nirmatrelvir-ritonavir [<a href="#rid119">119,120</a>]; the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.idsociety.org%2Fpractice-guideline%2Fcovid-19-guideline-treatment-and-management%2Fmanagement-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid%2F&amp;token=PF79Qll0ZEcrXcSejnNlpjmmAcZtkSqbitBDj84VC5bu6mdOhSNiF8p6PjXFyhEkO8m4vCGfxBm7ZrrXxsLfawErA3QqZx0G1MwQTFPeOnb7wZ3dOas4s1vgAHjI9GfESw5tsA%2FwnsBpccOZkoMx08RjvQIT32iKlXnwgKIxHvI%3D&amp;TOPIC_ID=128389" target="_blank">Infectious Diseases Society of America</a> also provides guidance for the management of drug interactions with nirmatrelvir-ritonavir [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent2">The decision to use <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a> in patients with uncontrolled/untreated human immunodeficiency virus (HIV) should factor in the potential risk of causing HIV protease inhibitor resistance [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent2">There have been reports of recurrent symptoms and/or a positive SARS-CoV-2 test ("rebound" COVID-19) two to eight days after completion of treatment with <a class="drug drug_pediatric" data-topicid="134696" href="/z/d/drug information/134696.html" rel="external">nirmatrelvir-ritonavir</a> [<a href="#rid122">122</a>]. In such cases, the CDC recommends that the isolation period be restarted. Limited evidence suggests that recurrent disease is mild, and evidence that another course of antiviral therapy is beneficial is lacking. In addition, recurrent symptoms also occur in patients who are not treated with nirmatrelvir-ritonavir or other medications [<a href="#rid123">123-125</a>]. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Isolation at home'</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on '"Rebound" COVID-19 after nirmatrelvir-ritonavir treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remdesivir</strong><strong> </strong>— IV <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> is commercially available and another option for nonhospitalized children with a positive test for SARS-CoV-2 who have symptomatic mild-to-moderate COVID-19 and are at risk for progression to severe disease [<a href="#rid2">2,70</a>]. It is approved for children ≥28 days who weigh ≥3 kg [<a href="#rid49">49</a>]. In a randomized trial in nonhospitalized adults with at least one risk factor for disease progression, remdesivir reduced the risk of hospitalization [<a href="#rid126">126</a>]. Data in children are limited [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">Remdesivir</a> should be initiated as soon as possible and within seven days of symptom onset. It is dosed according to weight as follows [<a href="#rid50">50</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥3 to &lt;40 kg – 5 mg/kg IV day 1, followed by 2.5 mg/kg IV on days 2 and 3</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥40 kg – 200 mg IV on day 1, followed by 100 mg IV on days 2 and 3</p><p></p><p class="bulletIndent1">Given the three-day regimen, <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> may be most feasible for children and adolescents residing in skilled nursing facilities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molnupiravir</strong> — <a class="drug drug_pediatric" data-topicid="134698" href="/z/d/drug information/134698.html" rel="external">Molnupiravir</a> is a nucleoside analogue that inhibits SARS-CoV-2 replication. It is available through <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F155054%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPIbMHcPXd5rIyY6xu0AU1A%2FJ4x0mO6Z7GoSagpV3B3lxssqAEFdyRovVvRwV6VgAwg%3D%3D&amp;TOPIC_ID=128389" target="_blank">EUA</a> for the treatment of mild-to-moderate COVID-19 in nonpregnant individuals ≥18 years of age who are at high risk for progression to severe disease and for whom other authorized treatments are not accessible or clinically appropriate [<a href="#rid127">127</a>]. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies of limited or uncertain benefit'</a>.) </p><p></p><p class="headingAnchor" id="H564076610"><span class="h3">Outpatient monoclonal antibody therapy</span><span class="headingEndMark"> — </span>Outpatient monoclonal antibody therapy is no longer available for the treatment of COVID-19. The FDA paused authorization for <a class="drug drug_pediatric" data-topicid="134986" href="/z/d/drug information/134986.html" rel="external">bebtelovimab</a> in November 2022 because it is not expected to neutralize Omicron subvariants BQ.1, BQ.1.1, and XBB, which are the predominant subvariants circulating in the United States [<a href="#rid108">108</a>].</p><p class="headingAnchor" id="H553133423"><span class="h2">Symptomatic and supportive care</span><span class="headingEndMark"> — </span>Symptomatic care for COVID-19 in the outpatient setting is similar to that for other upper respiratory or gastrointestinal clinical syndromes:</p><p class="bulletIndent1"><span class="glyph">●</span>Fever (see  <a class="medical medical_review" href="/z/d/html/5989.html" rel="external">"Fever in infants and children: Pathophysiology and management", section on 'Management of fever'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pain or discomfort – Either NSAIDs or <a class="drug drug_pediatric" data-topicid="13028" href="/z/d/drug information/13028.html" rel="external">acetaminophen</a> may be used as needed for symptomatic treatment of pain or discomfort</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upper respiratory tract infection (see  <a class="medical medical_review" href="/z/d/html/16629.html" rel="external">"The common cold in children: Management and prevention", section on 'Symptomatic therapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pharyngitis (see  <a class="medical medical_review" href="/z/d/html/2875.html" rel="external">"Acute pharyngitis in children and adolescents: Symptomatic treatment", section on 'Symptomatic treatment'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute gastroenteritis (see  <a class="medical medical_review" href="/z/d/html/5992.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Management and prevention", section on 'Management'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adequate vitamin D intake — Adequate intake of vitamin D is necessary for bone health. Vitamin D supplementation may be necessary to meet the recommended intake  (<a class="graphic graphic_table graphicRef71669" href="/z/d/graphic/71669.html" rel="external">table 8</a>), particularly for children with limited exposure to sunlight (eg, those remaining inside while self-isolating). However, the role of vitamin D in the treatment and prevention of COVID-19 is uncertain, and doses exceeding the upper level intake are <strong>not</strong> recommended [<a href="#rid2">2,128-131</a>]. (See  <a class="medical medical_review" href="/z/d/html/13915.html" rel="external">"Vitamin D and extraskeletal health", section on 'COVID-19'</a> and  <a class="medical medical_review" href="/z/d/html/2033.html" rel="external">"Overview of vitamin D"</a>.)</p><p></p><p class="headingAnchor" id="H1996450383"><span class="h2">Monitoring for deterioration</span><span class="headingEndMark"> — </span>Caregivers of children who are managed at home should be counseled about symptoms of clinical deterioration, which may occur suddenly after approximately one week of symptoms and should prompt urgent re-evaluation, ideally at a medical center with expertise in caring for children with COVID-19 [<a href="#rid20">20</a>].</p><p>Manifestations of clinical deterioration include [<a href="#rid100">100,101,132,133</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe respiratory distress, difficulty breathing (for infants: grunting, central cyanosis, inability to breastfeed)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain or pressure</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blue lips or face</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Findings associated with shock (eg, cold, clammy, mottled skin; new confusion; difficulty arousing; substantially reduced urine output)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inability to drink or keep down any liquids</p><p></p><p class="headingAnchor" id="H6180414"><span class="h2">Isolation at home</span><span class="headingEndMark"> — </span>Isolation at home is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Infection prevention in the home setting'</a> and  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p class="headingAnchor" id="H1246535226"><span class="h1">AVOIDANCE OF UNPROVEN INTERVENTIONS</span><span class="headingEndMark"> — </span>Neither <a class="drug drug_pediatric" data-topicid="12937" href="/z/d/drug information/12937.html" rel="external">azithromycin</a> nor <a class="drug drug_pediatric" data-topicid="13366" href="/z/d/drug information/13366.html" rel="external">hydroxychloroquine</a>/<a class="drug drug_pediatric" data-topicid="13147" href="/z/d/drug information/13147.html" rel="external">chloroquine</a> have been proven effective in improving symptoms or preventing progression in patients with COVID-19. We recommend not using them in the management of SARS-CoV-2 in children [<a href="#rid2">2,18,103,134-136</a>].</p><p>Investigational agents, including <a class="drug drug_pediatric" data-topicid="13025" href="/z/d/drug information/13025.html" rel="external">fluvoxamine</a> and <a class="drug drug_pediatric" data-topicid="13060" href="/z/d/drug information/13060.html" rel="external">ivermectin</a>, should be used only in the context of a clinical trial; evidence of benefit is lacking [<a href="#rid2">2,18,70,137-139</a>]. Misuse of forms of these agents not intended for humans (eg, veterinary ivermectin) may lead to severe toxicity, including death [<a href="#rid140">140-142</a>]. Although preliminary studies of fluvoxamine in adult patients suggest benefits in reducing hospitalization, death, and/or disease progression, additional data are needed before it can be recommended for children outside of a clinical trial. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies of limited or uncertain benefit'</a>.)</p><p class="headingAnchor" id="H3943617973"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>The type (eg, telehealth versus in-person visit with primary care provider or specialist), timing, and content of follow-up for children and adolescents recovering from acute SARS-CoV-2 infection is individualized according to underlying comorbidities, severity of illness, persistence of symptoms, and complications. We follow the guidance provided by the American Academy of Pediatrics (AAP) [<a href="#rid143">143</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children without multisystem inflammatory syndrome in children (MIS-C)</strong> – Children with &gt;4 days of symptoms (eg, fever, chills, myalgia, lethargy) and children who required hospitalization may require phone or video follow-up during isolation to ensure continued recovery [<a href="#rid143">143</a>]. After the isolation period is over and before return to physical activity, they should have an in-person visit. Children with asymptomatic or mild disease (&lt;4 days of symptoms) and resolution of symptoms can have follow-up by video, phone, or in person (after the isolation period is over) before return to physical activity.</p><p></p><p class="bulletIndent1">The follow-up visit should address [<a href="#rid143">143</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ongoing and newly developed symptoms, including cardiorespiratory symptoms, loss of smell or taste (may manifest in feeding changes in young children), neurodevelopmental symptoms (eg, motor, cognitive, language impairment; inattention; memory problems), fatigue, headache, and mental health sequelae [<a href="#rid143">143</a>]. In addition, children with a history of SARS-CoV-2 infection should be screened for diabetes symptoms (eg, increased thirst, increased hunger, frequent urination, weight loss, fatigue, abdominal pain, nausea, vomiting); SARS-CoV-2 infection has been associated with increased incidence of diabetes mellitus in some [<a href="#rid144">144-150</a>], but not all [<a href="#rid151">151</a>], studies.</p><p></p><p class="bulletIndent2">Children with ongoing symptoms and worrisome signs should be evaluated as clinically indicated (eg, for myocarditis or MIS-C, intracranial pathology in children with headache and worrisome features  (<a class="graphic graphic_table graphicRef79664" href="/z/d/graphic/79664.html" rel="external">table 9</a>)).</p><p></p><p class="bulletIndent2">Otherwise, we minimize diagnostic testing and provide supportive care focused on improving function (eg, by setting achievable goals) for the first 12 weeks of recovery [<a href="#rid143">143,152</a>]. Although persistent symptoms may be related to SARS-CoV-2 infection, they also may be related to the conditions of the pandemic (eg, social isolation, death of a family member, trauma of hospitalization, decreased physical activity) [<a href="#rid153">153-156</a>]. In longitudinal follow-up of a matched cohort of children and adolescents with SARS-CoV-2 infection, most symptoms that were reported at the time of diagnosis resolved within 6 to 12 months [<a href="#rid157">157</a>]. (See  <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children", section on 'Post-COVID-19 condition ("long COVID")'</a>.)</p><p></p><p class="bulletIndent2">Additional testing or referral to a multidisciplinary post-COVID-19 clinic may be warranted for children whose symptoms persist for &gt;12 weeks [<a href="#rid143">143</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Return to activities of daily living (eg, school, work, recreational activities)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Behavioral and mental health surveillance [<a href="#rid48">48,158</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Guidance for return to activity (eg, school, sports, employment), including provision of support as indicated (eg, gradual return to school).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Before returning to physical activity (eg, organized sports training, practice, or competition; physical education class within school; recreational sports), children should be evaluated by their clinician for cardiac symptoms (eg, chest pain, palpitations, syncope, shortness of breath out of proportion to respiratory tract illness) because of the possibility cardiac complications of SARS-CoV-2 [<a href="#rid159">159</a>]. Return to play following COVID-19 is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/130803.html" rel="external">"COVID-19: Return to sport or strenuous activity following infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>COVID-19 immunization (if eligible) and catch-up of routine immunizations (if necessary). (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Catch-up schedule'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reinforcement of strategies to prevent infection. (See <a class="local">'Prevention of transmission'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Education about symptoms that should prompt re-evaluation. (See <a class="local">'Symptomatic and supportive care'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Healthy habits – Adequate nighttime sleep, maintaining a consistent daily schedule, adequate hydration and nutrition, and avoidance of alcohol and drugs.</p><p></p><p class="bulletIndent1">Testing for SARS-CoV-2 after recovery is not recommended unless the child or adolescent is newly symptomatic or has been exposed to someone recently diagnosed with SARS-CoV-2 infection. A negative SARS-CoV-2 test is not necessary to discontinue isolation but may be used to determine when masking can be discontinued [<a href="#rid160">160</a>]. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Isolation at home'</a> and  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children with MIS-C</strong> – Follow-up of children with MIS-C is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129614.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome", section on 'Follow-up'</a>.)</p><p></p><p class="headingAnchor" id="H4133885036"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H2040475473"><span class="h2">Prevention of transmission</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing transmission</strong> <strong>from infected mother to newborn</strong> – Prevention of transmission from infected mother to newborn after delivery is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129846.html" rel="external">"COVID-19: Intrapartum and postpartum issues", section on 'Postpartum care of infected patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing transmission</strong> <strong>from children with documented or suspected COVID-19 </strong>–<strong> </strong>Infection prevention for persons with SARS-CoV-2 infection in health care and home settings is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing transmission</strong> <strong>from asymptomatic children with potential exposure</strong> – The management of asymptomatic children with potential exposure to COVID-19, including wearing masks and monitoring for symptoms, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Post-exposure management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing transmission</strong> <strong>from asymptomatic frontline workers to household members</strong> – Specific guidance for prevention of transmission from asymptomatic frontline/essential workers with potential unrecognized exposure to SARS-CoV-2 to household members is lacking. In addition to COVID-19 vaccination, adherence to prevention strategies during work (eg, use of personal protective equipment, handwashing) is recommended. The Centers for Disease Control and Prevention (CDC) provides additional recommendations to prevent transmission of COVID-19 outside of work and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprevent-getting-sick%2Fprevention.html&amp;token=6h%2BCkGBSSZq%2Fm0MqmAUQs2d36VuEL1tN3ZizAE7%2FVRA4ZV1taGOBicu%2FqpbJBtJ1UZuIFmmWnzLdI5NEYJ2wnSJnCFsHaDHX1XNSb06jnNU%3D&amp;TOPIC_ID=128389" target="_blank">personal prevention strategies</a> [<a href="#rid160">160,161</a>]. The CDC recommends that individuals who live in areas with a high <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fyour-health%2Fcovid-by-county.html&amp;token=FDVED5iDTlE2%2BRmuCec5y0O2YA8uijEm7O9JCyFUvajEEvmijU9SVAaMi%2BJ6DxQPd4e4qQGZrGLG21NIHvW8V6NZIIak0h9DAZVVTlW2bqA%3D&amp;TOPIC_ID=128389" target="_blank">COVID-19 community level</a> wear a mask indoors in public [<a href="#rid162">162-164</a>]. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1">In addition, health care and other frontline workers may choose to implement additional measures after work (eg, changing out of work clothes and shoes and/or showering before contact with household members), although it is uncertain whether these practices lower the risk of transmission. Physical distancing, use of face masks, and/or improving <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprevent-getting-sick%2FImproving-Ventilation-Home.html&amp;token=MvVsTXwZn733AsqIGI7HqBoHmDhAjspg3aEGQaXOx6bEIJ3UgY9ulFoeb7k%2BMzPYxyDnmZIUotiQ5EzCL0%2BPvFOXbHAWD1vJXSFD2MHtt1D33Nr2AECKULTo%2FdD1651a&amp;TOPIC_ID=128389" target="_blank">ventilation</a> in the home also may be warranted, particularly if household members are at increased risk for severe infection [<a href="#rid160">160,165,166</a>]. (See  <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children", section on 'Risk factors for severe disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventing transmission to asymptomatic children without known exposure</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Routine health care</strong> – Routine well-child care is necessary for preventive health care and screening (eg, newborn screening immunizations, anticipatory guidance, developmental surveillance). We agree with the American Academy of Pediatrics (AAP) that routine care should continue during the COVID-19 pandemic [<a href="#rid167">167,168</a>].</p><p></p><p class="bulletIndent2">Strategies that can be used to separate children who are well from children who are ill or possibly ill include [<a href="#rid167">167,169-171</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Scheduling home visits</p><p class="bulletIndent3"><span class="glyph">-</span>Use of telemedicine</p><p class="bulletIndent3"><span class="glyph">-</span>Scheduling well-visits in the morning and sick visits in the afternoon</p><p class="bulletIndent3"><span class="glyph">-</span>Seeing children for sick visits in a different part of the clinic, designated examination rooms, or at a different office site (or practice)</p><p></p><p class="bulletIndent2">The AAP provides <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpublications.aap.org%2Fpediatrics%2Farticle%2F148%2F3%2Fe2021053129%2F181044&amp;token=VAZTsfFDgY26gEGPhbfiGa7dtYlQPCv8tOkTlecryvQzb7d3PzA627HwS7YOE%2BUByy1SD1uWzFpSf5Pt94YMlJzGeQ4w2Pld66p%2FdwCBgtE%3D&amp;TOPIC_ID=128389" target="_blank">information and resources about telemedicine</a> [<a href="#rid170">170</a>], including information about <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdownloads.aap.org%2FDOPA%2FTelehealth_2_rev.pdf&amp;token=9%2B1WzAVoaNG6j5eyEhahpKDo9n%2FdvwSBdRvIxbKLT9wLTR8qqqJ5isEp5KhhbE4DnyAZDGHtXx0Fblco9q73LA%3D%3D&amp;TOPIC_ID=128389" target="_blank">state-by-state payer policies</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gathering with other children</strong> – When gathering with children from other households, caregivers should consider whether family members or close contacts are at increased risk for severe COVID-19 disease (eg, immunocompromised or with certain underlying conditions) and the COVID-19 vaccination status of individual family members [<a href="#rid172">172</a>].</p><p></p><p class="bulletIndent2">Steps caregivers can take to protect their children include [<a href="#rid161">161</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Getting eligible children vaccinated against COVID-19 (see  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Children'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Gathering outside when possible</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Keeping children ≥6 feet from people from other households when they are indoors in public</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Avoiding poorly ventilated spaces and crowds</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Having children ≥2 years of age wear a face mask in public spaces in areas where the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fyour-health%2Fcovid-by-county.html&amp;token=FDVED5iDTlE2%2BRmuCec5y0O2YA8uijEm7O9JCyFUvajEEvmijU9SVAaMi%2BJ6DxQPd4e4qQGZrGLG21NIHvW8V6NZIIak0h9DAZVVTlW2bqA%3D&amp;TOPIC_ID=128389" target="_blank">COVID-19 community level</a> is high (see <a class="local">'Use of face masks'</a> below)</p><p></p><p class="headingAnchor" id="H2824375302"><span class="h2">Use of face masks</span><span class="headingEndMark"> — </span>The CDC recommends that individuals ≥2 years of age wear a high-quality, well-fitting, and comfortable face mask if they have symptoms, have tested positive for SARS-CoV-2, or have been exposed to someone with COVID-19 [<a href="#rid163">163</a>] (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Wearing masks in the community'</a>.)</p><p>In addition, although local regulations should be followed, the recommends that individuals ≥2 years of age wear a high-quality, well-fitting, and comfortable face mask when they are in indoor public settings in areas where the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fyour-health%2Fcovid-by-county.html&amp;token=FDVED5iDTlE2%2BRmuCec5y0O2YA8uijEm7O9JCyFUvajEEvmijU9SVAaMi%2BJ6DxQPd4e4qQGZrGLG21NIHvW8V6NZIIak0h9DAZVVTlW2bqA%3D&amp;TOPIC_ID=128389" target="_blank">COVID-19 community level</a> is high [<a href="#rid163">163,164,173</a>]. Masks that are most protective, fit well, and will be worn consistently are preferred; the preferred mask type may vary from person to person [<a href="#rid174">174</a>]. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Variants of concern'</a>.)</p><p>When the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fyour-health%2Fcovid-by-county.html&amp;token=FDVED5iDTlE2%2BRmuCec5y0O2YA8uijEm7O9JCyFUvajEEvmijU9SVAaMi%2BJ6DxQPd4e4qQGZrGLG21NIHvW8V6NZIIak0h9DAZVVTlW2bqA%3D&amp;TOPIC_ID=128389" target="_blank">COVID-19 community level</a> is medium or low and local regulations do not require masks in indoor public settings, the CDC and AAP suggest that decisions about wearing masks in indoor settings should be individualized according to the child and family's circumstances (eg, whether household and other contacts are vaccinated, immunocompromised, at high risk of severe disease) [<a href="#rid164">164,166</a>].</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.healthychildren.org%2FEnglish%2Fhealth-issues%2Fconditions%2FCOVID-19%2FPages%2FCloth-Face-Coverings-for-Children-During-COVID-19.aspx&amp;token=piFifQKeKWUAYtuNjh5BhK5FWN4dN%2FTL%2FCMxFFn%2FPuBz%2FaiHDSbK24Z1Eoym%2FX3E9kpvgrC3Le%2BZuIr65Wa3RdCrffCB4NeJ5uzsMk2hMJ2hCKJuHAnPeWe%2BYVlATfSQLgkSzbUKb4wp%2B5UqbvHxs4PpP4JOZaI26vTYPRnLY%2Bk%3D&amp;TOPIC_ID=128389" target="_blank">AAP</a> provides additional information about face masks for children, including tips for increasing proper wearing and use <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.healthychildren.org%2FEnglish%2Ftips-tools%2Fask-the-pediatrician%2FPages%2FDoes-my-unvaccinated-child-still-have-to-wear-a-mask.aspx&amp;token=AQP3Fc941w4xcsbaayYRtuaKlR9ITwYqCvHkzBnMUyCReNFN7Xqz3WIhD8mnYtQj6GMSYXWVHHCMnbrPEzLm9B9hXt%2BKjQ2oi5urxCzUxhmAE1Y48mSpFFeBXUfinhEkfkXQwAOhPvztxWpGbUYscq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=128389" target="_blank">and guidance for indoor and outdoor mask use in unvaccinated children</a>. Recommendations from the CDC and AAP regarding face masks for children and adolescents in the school setting are provided below. (See <a class="local">'In-person school and child care'</a> below.)</p><p>The WHO provides the following age-based guidance for use of well-fitting masks in areas with community or cluster transmission when interacting with individuals outside the immediate household (independent of vaccination status) [<a href="#rid175">175</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age 5 years and younger; children with conditions that make it difficult to wear a mask or interfere with wearing a mask (eg, cognitive or respiratory impairment, developmental disorder); children who are doing physical activities that may affect breathing (eg, running, jumping) – Masks are not required</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age 6 to 11 years – Mask use is recommended in:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Indoor settings if the ventilation is poor, not properly maintained, or cannot be assessed</p><p class="bulletIndent2"><span class="glyph">•</span>Indoor settings if the ventilation is adequate but physical distancing of ≥1 meter cannot be maintained</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age 12 and older – Mask use is recommended:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In crowded, enclosed, or poorly ventilated spaces</p><p class="bulletIndent2"><span class="glyph">•</span>Following a recent exposure to COVID-19 when sharing a space with others</p><p class="bulletIndent2"><span class="glyph">•</span>When sharing a space with someone who has COVID-19 or has symptoms of COVID-19</p><p class="bulletIndent2"><span class="glyph">•</span>In individuals at high risk of severe complications from COVID-19</p><p></p><p>Additional details are available in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2FWHO-2019-nCoV-ipc-guideline-2023.1&amp;token=d2hdX7EUGDPDm8tX5G3XpPqi1vW%2BU6hE9dTVAIx0H%2FQMbeYYdZFGSYskE7NtU%2B9jNb7FiVhOVg00N8B95QT%2Fn86O4yMQE%2BkrPy7YF6MRrDavALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=128389" target="_blank">living guideline</a> [<a href="#rid175">175</a>]. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Wearing masks in the community'</a>.)</p><p class="headingAnchor" id="H709232992"><span class="h2">Safe use of hand sanitizer</span><span class="headingEndMark"> — </span>Although washing hands with soap and water is preferred whenever possible, alcohol-based hand sanitizer is safe for use in children when the sanitizer is used according to the information on the Drug Facts label; there is no cause for concern if children eat or lick their hands after the hand sanitizer has fully dried [<a href="#rid176">176</a>].</p><p>Counseling regarding safe use of alcohol-based hand sanitizer includes [<a href="#rid176">176-178</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Use hand sanitizer in a well-ventilated area; inhalation of alcohol vapors may be associated with adverse effects (eg, dizziness, nausea, headache) [<a href="#rid177">177</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoid homemade hand sanitizer, which may be ineffective or cause skin burns</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Keep hand sanitizers out of the reach and sight of children</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supervise the use of hand sanitizer in children younger than six years to avoid ingestion and/or eye exposure from touching the eyes or splashing</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic toxicity – Even a small amount of liquid hand sanitizer can cause alcohol poisoning in children (including hypoglycemia) [<a href="#rid179">179</a>]. (See  <a class="medical medical_review" href="/z/d/html/6486.html" rel="external">"Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects"</a> and  <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent2">Hand sanitizers made with isopropyl alcohol (isopropanol) may be more toxic than those that contain ethanol (ethyl alcohol) [<a href="#rid180">180</a>]. Hand sanitizers that contain methanol (methyl alcohol) or methylated spirits should be avoided; ingestion of methanol can be life threatening [<a href="#rid180">180-182</a>]. The US Food and Drug Administration (FDA) has noted an increase in hand sanitizer products that are labeled to contain ethanol but have tested positive for contamination with methanol or 1-propanol. The FDA provides a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updates-hand-sanitizers-consumers-should-not-use&amp;token=oR6XLVRDm1kgiZQzrndvQJTEKPXQj4%2BOZMWTJlEH318uf%2F3q%2FO7uot3nTdMZ5V8datv3NrOSOOVhaR5bw3T%2FfumRyg5Sso8jJOiEQLAZKIloyT3wyUFk78ly7Ib0UTNG&amp;TOPIC_ID=128389" target="_blank">list of these products</a> and other products that contain potentially harmful ingredients on its <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-updates-hand-sanitizers-consumers-should-not-use%23products&amp;token=TkvPrZjKFzO88sIgo79WgcDsdLmdjQPaiR5QlH%2BMkGFgThmsCC38HzwslFsl11smVndUlisg7JiEThOKvquIrJpAjmKj1k8YpD6kdCRwmPLHj3k5W7WBh7HlMp2sPKuxcupxwFkwqpTTte%2FC92xG8A%3D%3D&amp;TOPIC_ID=128389" target="_blank">website</a>. In addition, the FDA has placed all <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Fcoronavirus-covid-19-update-fda-takes-action-place-all-alcohol-based-hand-sanitizers-mexico-import&amp;token=YMFQ6BWdmBkPbU2ncaCHJuoUkRbOeTVVzsZKuavVOxQPqPz2ytyYupwY2gAu55%2BTvpNEWYXSTuStJG9Xbfb3D5Pbv5vAR5RuiEHFNNgPtysZYx6h42KO7AQoszscBUy4t85maFIaTqZt3lv60KTKgjh8%2FxD6kHyuhMd22Pm2Nf0%3D&amp;TOPIC_ID=128389" target="_blank">alcohol-based hand sanitizers from Mexico on import alert</a> because of frequent contamination with toxic ingredients, including methanol and 1-propanol [<a href="#rid183">183</a>]. (See  <a class="medical medical_review" href="/z/d/html/336.html" rel="external">"Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/126052.html" rel="external">"Methanol and ethylene glycol poisoning: Management"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eye injury – Eye exposure may result in severe injury [<a href="#rid178">178,184-186</a>]. In the event of eye exposure, rinse the eyes immediately with gently running water (eg, from a sink tap, water bottle, emergency shower) for at least 15 to 20 minutes. Patients who develop symptoms after rinsing (eg, redness, pain, irritation, visual impairment, photophobia) should seek urgent eye examination [<a href="#rid178">178</a>].</p><p></p><p class="headingAnchor" id="H2985427161"><span class="h2">Pre-exposure prophylaxis</span></p><p class="headingAnchor" id="H1906637348"><span class="h3">SARS-CoV-2 immunization</span><span class="headingEndMark"> — </span>SARS-CoV-2 immunization is the optimal method of pre-exposure prophylaxis for eligible individuals  (<a class="graphic graphic_table graphicRef130711" href="/z/d/graphic/130711.html" rel="external">table 10</a> and <a class="graphic graphic_figure graphicRef138339" href="/z/d/graphic/138339.html" rel="external">figure 1</a>). The Centers for Disease Control and Prevention provide <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fchildhood-vaccination-toolkit.html&amp;token=CxqOV8T9PVQLLysN%2BQu1iTdNMpKMHAyMb5Nykq1jinsVvHOdjmu7f1JgHpyFuPCkDg4m%2F9NNbtmkY0t7fogELjONN%2BudL%2Flr9Oeq53Dk7AM%3D&amp;TOPIC_ID=128389" target="_blank">multiple resources</a> for pediatric health care professionals.</p><p>SARS-CoV-2 immunization is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">"COVID-19: Allergic reactions to SARS-CoV-2 vaccines"</a>.)</p><p class="headingAnchor" id="H3620851252"><span class="h3">Pre-exposure prophylaxis with monoclonal antibodies</span><span class="headingEndMark"> — </span>In the United States, the Food and Drug Administration revoked <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F154701%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPM4J23swMaMCSgQqYDMLSgsYTuYxrFLZk35VdF2NeWp%2F5VvR9YX5pqv02wGxOuKoVQ%3D%3D&amp;TOPIC_ID=128389" target="_blank">emergency use authorization</a> for copackaged <a class="drug drug_pediatric" data-topicid="134628" href="/z/d/drug information/134628.html" rel="external">tixagevimab-cilgavimab</a> for pre-exposure prophylaxis because it is unlikely to be active against the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovid.cdc.gov%2Fcovid-data-tracker%2F%23variant-proportions&amp;token=DviBTzQNV61nIfudo5ZW%2F94ZVcLUx8TzUmrsLth4JU8RfSWcSDATQiYzDP63SgbrqwYUg1gY7egwR3L96Rbo%2Fg%3D%3D&amp;TOPIC_ID=128389" target="_blank">most prevalent Omicron subvariants</a>  (<a class="graphic graphic_table graphicRef131216" href="/z/d/graphic/131216.html" rel="external">table 4</a>) [<a href="#rid187">187</a>]. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Monoclonal antibodies ineffective for pre-exposure prophylaxis'</a>.)</p><p class="headingAnchor" id="H600689585"><span class="h2">Postexposure prophylaxis</span></p><p class="headingAnchor" id="H3079160672"><span class="h3">Monoclonal antibodies</span><span class="headingEndMark"> — </span>No monoclonal antibodies are approved or authorized for postexposure prophylaxis in the United States. In late January 2022, the FDA paused the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F145802%2Fdownload&amp;token=8RYIFfyLhIBYEqeX7m6uPPIcmd%2BjegGoPPgMvzukYB5Gr36CINrEJrWQ34bqWiwlssqAEFdyRovVvRwV6VgAwg%3D%3D&amp;TOPIC_ID=128389" target="_blank">emergency use authorization</a> (EUA) for combination <a class="drug drug_pediatric" data-topicid="130800" href="/z/d/drug information/130800.html" rel="external">bamlanivimab-etesevimab</a> and combination <a class="drug drug_pediatric" data-topicid="130226" href="/z/d/drug information/130226.html" rel="external">casirivimab-imdevimab</a> due to the widespread high frequency of circulation of the Omicron variant, which is highly unlikely to be susceptible to bamlanivimab-etesevimab or casirivimab-imdevimab  (<a class="graphic graphic_table graphicRef131216" href="/z/d/graphic/131216.html" rel="external">table 4</a>) [<a href="#rid105">105,188,189</a>].</p><p class="headingAnchor" id="H814065613"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>We avoid postexposure prophylaxis with <a class="drug drug_pediatric" data-topicid="13366" href="/z/d/drug information/13366.html" rel="external">hydroxychloroquine</a>. In a meta-analysis of three randomized trials [<a href="#rid190">190-192</a>], rates of symptomatic infection (approximately 9 percent), hospitalization (&lt;1 percent), and death (&lt;1 percent) were similar in hydroxychloroquine and placebo groups [<a href="#rid18">18</a>].</p><p>Other agents for prevention of SARS-CoV-2 are being evaluated in clinical trials, but none has been proven effective in children. Postexposure prophylaxis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'No role for post-exposure prophylaxis'</a>.)</p><p class="headingAnchor" id="H1860616841"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2461445392"><span class="h2">Children with special health care needs</span><span class="headingEndMark"> — </span>The American Academy of Pediatrics provides information about <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fcaring-for-children-and-youth-with-special-health-care-needs-during-the-covid-19-pandemic%2F&amp;token=XyPEs5qrB174Nx95dev2nN1TDkOqXviLD1kq6A2dl2Cz7wQ6TcId0rc%2BiOumyk1Nuhxl7SXpAzyRTziNWqtPDH6%2B1M9L93wmJyXT03ZICSw95g%2Fgqyy6Xp%2BfbKX%2FXdnYVkDAgET2MhmWs454IBbt05oNPXHvYxqmS%2BiGY%2Fx%2F0UCYfeEu07%2BxeLzd%2FBjs0e85&amp;TOPIC_ID=128389" target="_blank">caring for children and youth with special health care needs during the COVID-19 pandemic</a> [<a href="#rid193">193</a>].</p><p>Closure of school may be particularly challenging for children and youth with special health care needs, who were receiving services at school (eg, speech therapy, behavior, mental health services) and/or have barriers to remote learning (eg, lack of access to a laptop/tablet or the internet, language barrier) [<a href="#rid194">194</a>]. In the United States, pediatric health care providers can review the child's Individualized Education Program to help the caregiver determine what services the child should be receiving (including compensatory services). A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsites.ed.gov%2Fidea%2Fidea-files%2Fsupplemental-fact-sheet-addressing-risk-covid-19-preschool-elementary-secondary-schools-serving-children-disabilities-march-21-2020%2F&amp;token=Cl5h0OnFgIxX%2FLMKXMQc5npx9lg7aS8Jgb7qxoKk9f%2FqrOabHgU%2Ft5s%2BIm3tU4qPAyXbsX%2FciT2gv%2BpYynXVy9xIWDvET9A3y6Y8ni5den6mRXCIf6NPCGbSYEwfr17vCbp91r%2FGdmko7UzsSK5UeFeo4ClIs1zoIX1pf9tysS4%3D&amp;TOPIC_ID=128389" target="_blank">fact sheet</a> from the Department of Education provides additional information. (See  <a class="medical medical_review" href="/z/d/html/626.html" rel="external">"Definitions of specific learning disorder and laws pertaining to learning disorders in the United States", section on 'Individuals with Disabilities Education Act'</a>.)</p><p>Consensus priorities for safer in-person school for children with medical complexity include [<a href="#rid195">195</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Encouraging all school personnel in close proximity with children with complex health needs to be vaccinated against COVID-19 and to wear a mask (even if they are vaccinated)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assigning and maintaining individual seats for the children with medical complexity during transportation to and from school</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ensuring that each child has their own medical equipment or single-use disposable equipment at school</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discussing COVID-19 mitigation strategies in Individualized Education Plan meetings; the strategies should be based upon the child's daily routines and should include contingency plans</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing families the opportunity to switch from in-person to virtual or homebound school based on COVID-19 spread or illness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identifying circumstances during which the child should remain home</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ensuring a respiratory protection plan is in place for school staff performing high-risk care (eg, nebulized treatments, tracheostomy suctioning)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Educating school staff and families about the increased risks of COVID-19 for children with complex health needs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing at-school COVID-19 testing for staff and students</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Having at least one medical staff member available to address acute COVID-19 symptoms or questions</p><p></p><p class="headingAnchor" id="H2781207514"><span class="h2">Children with attention deficit hyperactivity disorder</span><span class="headingEndMark"> — </span>The European attention deficit hyperactivity disorder (ADHD) guidelines group provides <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanchi%2Farticle%2FPIIS2352-4642%2820%2930110-3%2Ffulltext&amp;token=3XudTKDaNg3wqS%2FxJS59mFxwTESbPHIDYFVeIRNG2fyabsf9yd7yLlHcxbxnNDQ310WTbMDz%2FdZNrCOzDcQj2W0HPGoF4S7KvbZ3IGT41eoxlm455%2FxDbEXZFXlXx9IR&amp;TOPIC_ID=128389" target="_blank">guidance for management of ADHD during the COVID-19 pandemic</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanchi%2Farticle%2FPIIS2352-4642%2820%2930144-9%2Ffulltext&amp;token=G9S%2BcDnPtqGuG%2FBCAuikQI2tzLJZJ%2BYnUu9Ysxx%2B8nuTNWeHMqRuWUjKZ07%2FBkhPRUF0zK2FBsOCallgGi1qUtrykkFnJqTpE7NgXoXeQ%2F%2F%2FCGcqh1u6Ucx7b6r7aS4%2B&amp;TOPIC_ID=128389" target="_blank">guidance for starting stimulants or atomoxetine in children who did not have an in-person cardiovascular assessment before the pandemic</a> [<a href="#rid196">196,197</a>].</p><p>The AAP provides <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Finterim-guidance-on-supporting-the-emotional-and-behavioral-health-needs-of-children-adolescents-and-families-during-the-covid-19-pandemic%2F&amp;token=fb0vyterW05C17N8h4vnnrbIjuhIoLcLp7Zj24RVrcX6wnarqdnhaCOK%2BjKD7glbPvWQXRgLPzeYlqRxGstntocv3WeMV7KWcA1ObH6fCDaar4A6zzp8Mo6qOyRZAMHpbsZvuf5iiFyY4hGxfWgigGijewb4olPOKsjdXsJzEhJvJMZMQzKi7jArNKTq5Ul079RbyX5uUDvRLGeFw3a87w%3D%3D&amp;TOPIC_ID=128389" target="_blank">suggestions to support students with special needs, including ADHD, and their families</a>.</p><p class="headingAnchor" id="H4095420602"><span class="h2">Children with rheumatic disease</span><span class="headingEndMark"> — </span>The American College of Rheumatology has issued <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.rheumatology.org%2Fannouncements&amp;token=bvhiNvboZByLg75vNseaJTxJSRsZ9VlsMj%2BJZ1n%2FpXqn9AEjoyouiNbibaxfSe1xszqummXQseMuEbZDZ0savw%3D%3D&amp;TOPIC_ID=128389" target="_blank">guidance regarding ongoing management of rheumatic disease</a> in children during the COVID-19 pandemic according to their clinical status (eg, without exposure or infection, with close/household exposure, with asymptomatic infection, with symptomatic infection) [<a href="#rid198">198</a>].</p><p class="headingAnchor" id="H1237049283"><span class="h2">Children involved with the child welfare system</span><span class="headingEndMark"> — </span>The AAP provides <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fguidance-for-children-and-families-involved-with-the-child-welfare-system-during-the-covid-19-pandemic%2F&amp;token=%2FZfvpGpuTGBzLMxxwJ%2F%2FA9VWUtnL6HByWGm9a3FBLwqC5FJlG%2FcyKCWauBfGfrviqBg2qH%2BrBINVcgrqzuBRxQ%2BVa3CvQOi4opfVzAowo8hAJzsZWl5B9YdtQSw1kyejybwei5S5K6jTEKN7FKHsI9QO2as2iKNSPeGjPrtINu3Lear%2F5qCQKpwBsECAud%2Fg&amp;TOPIC_ID=128389" target="_blank">guidance for children and families involved with the child welfare system</a> during the COVID-19 pandemic [<a href="#rid199">199</a>].</p><p class="headingAnchor" id="H1825157828"><span class="h1">ADDRESSING OR MITIGATING INDIRECT EFFECTS OF THE PANDEMIC</span></p><p class="headingAnchor" id="H2465608763"><span class="h2">Disruption of immunization</span><span class="headingEndMark"> — </span>Although the United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fpartners%2Froutine-immunizations-lets-rise.html%23%3A%7E%3Atext%3DDuring+the+COVID-19+pandemic%2Cyet+recovered+among+all+groups.&amp;token=0PsVVT%2Fk36ERUFRlvkDhnfByH%2FrhH90Wz3TcfgJfUV%2BmA4EDFI24s%2FRGjUVVJ8IoIArPjCFmfffAuWKIKQ%2BGbxpTikkm7QL5ivKoEaNjQkUrhBwNqO4eMwA%2Bzrx7pP1%2BvAaluIf7RbMmJ%2Bh%2BlfM4WITTIpQpAFnvPWHJhKGbU9FCfBVxv2iuFRjX2lgMXxPe&amp;TOPIC_ID=128389" target="_blank">Centers for Disease Control and Prevention</a> (CDC) and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fimmunization-as-an-essential-health-service-guiding-principles-for-immunization-activities-during-the-covid-19-pandemic-and-other-times-of-severe-disruption&amp;token=PdZ%2B%2B5tv%2BneG37KGTfXW7MWxEKjLLtVgP9uCuqGky1mSgpAuuNR2c7fQtPucuGLRTinaaUGaGs47vfikzSYNePyD%2FGBRjFAxccm3jiHRQZMBYRksu3UF7FvESvDEtOb%2BmGyd5Kps%2B8SNX2sEjoYNq2KNCuGNTX6F0pQGOV4KCFAYFd5Fe1G3c18GfN9ZZa10&amp;TOPIC_ID=128389" target="_blank">World Health Organization</a> (WHO) consider routine vaccination an essential preventive care service that should not be delayed because of the COVID-19 pandemic, routine immunization of children and adolescents has decreased [<a href="#rid200">200</a>]. Disruption of immunization services increases the risk of outbreaks of vaccine-preventable illnesses [<a href="#rid201">201</a>]. Children who have recovered from acute COVID-19 infection can receive routine childhood immunizations as soon as they have completed isolation. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.)</p><p>Adherence to recommendations for infants born to women who are hepatitis B surface antigen (HBsAg) positive or whose HBsAg status is unknown is particularly important for prevention of mother-to-child transmission of hepatitis B virus, especially if the delivery occurs at an unplanned facility or is attended by staff who are not knowledgeable about managing infants born to mothers who are HBsAg positive [<a href="#rid202">202</a>]. (See  <a class="medical medical_review" href="/z/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Benefits of vaccines'</a> and  <a class="medical medical_review" href="/z/d/html/101483.html" rel="external">"Hepatitis B virus immunization in infants, children, and adolescents", section on 'Routine infant immunization'</a>.)</p><p>Resources and guidance related to continuation of immunization during the pandemic are available from multiple professional groups, including the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fguidance-on-providing-pediatric-well-care-during-covid-19%2F&amp;token=BAp59wz63OXppHZ5n9fmUoFhJyz%2B%2FPDSBcmg8IlT3mH9JUlkJ4fA5%2F6UlEsaeAc9zzMuz7ArgxXnpOw7Q0FYIxCirS3IeGdpK7cEI%2B79E7M0FVaEk9F9n9jQzE7bCxZulJXNaA1kF%2BQVu7dtzBdEEg%3D%3D&amp;TOPIC_ID=128389" target="_blank">American Academy of Pediatrics</a> (AAP), the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.immunizationcoalitions.org%2Fresource-repository%2F&amp;token=bJ98wEjwYbR6KcGnbD%2BLofWqQfYaCt67NW6MVtVhW3CkwNdv4srG9OQQ2yoyH2qBxG96TYZeTav4zhcyQPKieq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=128389" target="_blank">National Network of Immunization Coalitions</a>, and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fpartners%2Froutine-immunizations-lets-rise.html%23%3A%7E%3Atext%3DDuring+the+COVID-19+pandemic%2Cyet+recovered+among+all+groups.&amp;token=0PsVVT%2Fk36ERUFRlvkDhnfByH%2FrhH90Wz3TcfgJfUV%2BmA4EDFI24s%2FRGjUVVJ8IoIArPjCFmfffAuWKIKQ%2BGbxpTikkm7QL5ivKoEaNjQkUrhBwNqO4eMwA%2Bzrx7pP1%2BvAaluIf7RbMmJ%2Bh%2BlfM4WITTIpQpAFnvPWHJhKGbU9FCfBVxv2iuFRjX2lgMXxPe&amp;TOPIC_ID=128389" target="_blank">CDC</a>.</p><p class="headingAnchor" id="H1247384627"><span class="h2">Physical health effects</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical activity and food security</strong> – The COVID-19 pandemic and measures to limit the spread of SARS-CoV-2 has been associated with decreased physical activity and increased screen time in children and adolescents, as well as food insecurity [<a href="#rid203">203-214</a>]:</p><p></p><p class="bulletIndent1">These effects can be mitigated through caregiver role-modeling of healthy behaviors, involving children in family activities, and promotion of self-discipline and self-sufficiency skills [<a href="#rid215">215-218</a>]. Guidance for physical activity and diet in children and adolescents is provided separately. (See  <a class="medical medical_review" href="/z/d/html/6474.html" rel="external">"Physical activity and strength training in children and adolescents: An overview", section on 'Physical activity'</a> and  <a class="medical medical_review" href="/z/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children"</a>.)</p><p></p><p class="bulletIndent1">The American Academy of Pediatrics (AAP) provides the following resources related to physical activity and healthy nutrition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fsupporting-healthy-nutrition-and-physical-activity-during-the-covid-19-pandemic%2F&amp;token=5QQ3J6LA%2FlPs0HJVcfJ%2FL%2FenLCMczM5F3XPZZaYKB8AY5h6zVfatArPEMlTuI7XFtcWX35BkxFSJ0VdEFicOXz148E%2F6j56s64r1ujad%2FVHKt8lvw2AmHKyYEPy6Ll1P1MB6E4RCsTdTtPv%2FCF36EPV%2BZSAgVEE%2Fs%2BiPcDUboUzb510NH1k3XPz57jIaCL1j&amp;TOPIC_ID=128389" target="_blank">AAP guidance on supporting healthy nutrition and physical activity during the COVID-19 pandemic</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fcovid-19-interim-guidance-return-to-sports%2F&amp;token=yFpBAq6WkdP692PSB%2FBQtF12O5A%2FkNvng%2Fxknvrv%2B8C5kcVtd8phbcy0woHC5QKAsFzPme6gN6nDZFzrzcRFpQNwb6CaAKdk9Dmode6okka0BDg2FXjSUowtE9NcCcM7qXp8IiSybu6KXu%2BQPHjWXQ%3D%3D&amp;TOPIC_ID=128389" target="_blank">AAP guidance on return to sports and physical activity</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fobesity-management-and-treatment-during-covid-19%2F&amp;token=PjX0sNlbBHSafZGfIJC4cRkENepS2ms%2BoTA5lmdcxnX4kRJSnvoMmrNq9TwbfToTyl5QUuw14qkzNrzuAXjBnegUpTrbmCeiLO99EwqCgv3HtmkjoZ7708nu0FNvf4pTSuKqb%2B4dwBHyABp1XegvLQ%3D%3D&amp;TOPIC_ID=128389" target="_blank">AAP guidance on obesity management and treatment during COVID-19</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffrac.org%2Faaptoolkit&amp;token=ZNhjFrGHvg%2FPI34v3TK1CNtK1zUby4zQvZMVwRwdM4dqrx8duD1yun2l9Yo96%2BVf&amp;TOPIC_ID=128389" target="_blank">AAP and Food Research and Action Center toolkit to address food insecurity</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Injury</strong> – The COVID-19 pandemic has been associated with increased risk of injury, including firearm injury and intentional or unintentional ingestion [<a href="#rid219">219-226</a>].</p><p></p><p class="headingAnchor" id="H248771453"><span class="h2">Mental health effects</span></p><p class="bulletIndent1"><strong>Mental health effects and associated factors</strong> – In observational studies of school-age children and adolescents, the COVID-19 pandemic has been associated with: increased symptoms of and/or hospitalization for depression, nonsuicidal self-injury, suicidality, anxiety, disordered eating, and insomnia; increased exposure to domestic and family violence; and increased use of alcohol or other drugs [<a href="#rid227">227-240</a>]. In a meta-analysis of 29 studies including &gt;80,000 children ≤18 years of age, 25 percent had clinically elevated depression symptoms and 20 percent had clinically elevated anxiety symptoms, approximately twice prepandemic estimates [<a href="#rid230">230</a>]. During the pandemic, the rates of emergency department visits for suicidality and positive primary care screening tests for symptoms of depression and suicide risk increased among adolescents and young adults [<a href="#rid229">229,241</a>].</p><p></p><p class="bulletIndent1">Poor mental health and suicidal behaviors are associated with exposure to adverse childhood experiences (ACEs), which has increased during the COVID-19 pandemic. The cross-sectional <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fhealthyyouth%2Fdata%2Fabes.htm&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLJKGJFh5fv4W603kMqT07BetKPA4UqirWAFdrkNmfRNjNnwZwpTFRYbA5mnWidBDdg%3D%3D&amp;TOPIC_ID=128389" target="_blank">Adolescent Behaviors and Experiences Survey</a> evaluated the association between specific ACEs (eg, emotional abuse, physical abuse, sexual violence, physical teen dating violence, electronic bullying, parent or caregiver job loss, food insecurity) and mental health/suicidal behaviors in 4390 high school students &lt;18 years of age during the COVID-19 pandemic [<a href="#rid242">242</a>]. Approximately 75 percent of students reported exposure to ≥1 ACE. Poor mental health and suicidal behaviors were associated with exposure to increasing numbers of ACEs and with exposure to particular ACEs (eg, emotional abuse, sexual violence, physical teen dating violence).</p><p></p><p class="bulletIndent1">School closures have been associated with increased risk of violence and vulnerability and decreased opportunities for referral to child protective services [<a href="#rid243">243-246</a>]. Vulnerable children and adolescents (eg, those who are homeless or in foster care; have a history of maltreatment; are lesbian, gay, bisexual, gender diverse, queer, questioning) are at particular risk for violence and adverse mental health effects [<a href="#rid247">247</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for and mitigation of mental health effects</strong> – Given the potential for mental health effects of COVID-19 and the COVID-19 pandemic, children and adolescents with COVID-19 require monitoring for possible mental health problems [<a href="#rid48">48,248</a>]. Symptoms of mental health problems include mood changes, irritability, and feelings of sadness or hopelessness [<a href="#rid48">48,242</a>].</p><p></p><p class="bulletIndent1">Clinicians can look for signs of caregiver stress, irritability, depression, and/or harsh responses to child behaviors during each clinical encounter [<a href="#rid244">244</a>]. They should ask about caregiver stress levels, methods to manage stress, social supports, resource stability, and substance use. If privacy can be assured during office or telemedicine visits, clinicians should also ask about exposure to abuse, household violence, and mental health [<a href="#rid48">48,247</a>].</p><p></p><p class="bulletIndent1">Clinicians can offer coping strategies (eg, deep breathing, calling a friend or family member), resources, and/or referrals to mental health providers to families who may benefit from these interventions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resources related to child care, emotional and behavioral health needs, prevention of violence, and mitigating long-term effects of ACEs include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Finterim-guidance-on-supporting-the-emotional-and-behavioral-health-needs-of-children-adolescents-and-families-during-the-covid-19-pandemic%2F&amp;token=fb0vyterW05C17N8h4vnnrbIjuhIoLcLp7Zj24RVrcX6wnarqdnhaCOK%2BjKD7glbPvWQXRgLPzeYlqRxGstntocv3WeMV7KWcA1ObH6fCDaar4A6zzp8Mo6qOyRZAMHpbsZvuf5iiFyY4hGxfWgigGijewb4olPOKsjdXsJzEhJvJMZMQzKi7jArNKTq5Ul079RbyX5uUDvRLGeFw3a87w%3D%3D&amp;TOPIC_ID=128389" target="_blank">American Academy of Pediatrics guidance on supporting the emotional and behavioral health needs during the COVID-19 pandemic</a> [<a href="#rid158">158</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.childcareaware.org%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlPtfJ4sPwcn0vuPGcIvEy29Ac8pdV8meIWZi38%2B%2FepIc&amp;TOPIC_ID=128389" target="_blank">Child Care Aware of America</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.end-violence.org%2Fprotecting-children-during-covid-19-outbreak&amp;token=2fwTZAsEWksyLeArchvonFTXXbBHgYBsFwSlOqMu2VXX8c7WIeZTMcAnOkz0SXfNDxQYUqYz8ftCuA9o3Sxq4B0hQGrGhaAupSEfbLhd8xo%3D&amp;TOPIC_ID=128389" target="_blank">Global Partnership to End Violence Against Children</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nctsn.org%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F3uo3MviNMIpSaDusiaVFb8%3D&amp;TOPIC_ID=128389" target="_blank">National Child Traumatic Stress Network</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The WHO: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2FWHO-2019-nCoV-Violence_actions-2020.1&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7uTgB8glbKNm0sPo4%2B8z2sYrFzJC4SIn9yZClp2w2ZANO7I2Jn5PP%2Bc%2BG77JHQS8%2FMFlh92wEriHt7Ax8Qb9Ge&amp;TOPIC_ID=128389" target="_blank">Addressing violence against children, women and older people during the COVID-19 pandemic: Key actions</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fstacks.cdc.gov%2Fview%2Fcdc%2F108199&amp;token=E6lW695Y1bjpwlD2WFwoOhMB4xzwb2c0E3ORCHybCw0XwuBG9qU3gyeUwZVlzlV3&amp;TOPIC_ID=128389" target="_blank">Children: The hidden pandemic 2021: A joint report of COVID-19 associated orphanhood and a strategy for action</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpublications.aap.org%2Fpediatrics%2Farticle%2F148%2F2%2Fe2021052580%2F179745%2FTrauma-Informed-Care&amp;token=auRgikbLOr5LtgIr%2BekVif%2FWuuGL%2Flv%2Bk6pETSSEQ3ILPDc1RmOXqUuz5N5XsG6AESyNIU2TJrGyiiJVWcmg%2Bl6mBD%2FTwMVSHYcPVpIU8viN2RR6L3JCf10svcr5BxEY&amp;TOPIC_ID=128389" target="_blank">The AAP clinical report on trauma-informed care</a></p><p></p><p class="headingAnchor" id="H3159563513"><span class="h2">Loss of a parent or caregiver</span><span class="headingEndMark"> — </span>Between March 2020 and May 2022, an estimated ≥7.5 million children lost a parent and ≥10.5 million children lost a parent or primary or secondary caregiver to COVID-19 [<a href="#rid249">249</a>]. Loss of a caregiver is an ACE and may affect long-term health and well-being [<a href="#rid250">250</a>]. Adverse effects may be mitigated through programs that promote safe, stable, nurturing relationships [<a href="#rid251">251</a>].</p><p>Resources for grieving children are available from [<a href="#rid252">252</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.healthychildren.org%2FEnglish%2Fhealthy-living%2Femotional-wellness%2FBuilding-Resilience%2FPages%2FGrieving-Whats-Normal-When-to-Worry.aspx&amp;token=0o6GFlWRITX6u1PR7bN2iwR8EgM7%2B19sKT8oNjOPyGDRuLxQXrbp140xz74OLmJwRCia0x7gS19tnTUkOwo10pGKxgtXD2eWWkBkzNa9jRFqmJ%2BJQlbAbywh2JfiFlfz62gTsqCpi1elLzX4apVv6X2ODzKb0YpvhXgwek0gLw0%3D&amp;TOPIC_ID=128389" target="_blank">The American Academy of Pediatrics and the Children's Hospital of Philadelphia</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fchildmind.org%2Fguide%2Fhelping-children-cope-with-grief%2F&amp;token=Kza%2FtpzYLQmkMER5J6hd97KeRsvqc0GT7sL5P%2BrUR7M%2BMwfSR3b9wAmA1CkW5QPZrqsEncea4NHXR8foK754cA%3D%3D&amp;TOPIC_ID=128389" target="_blank">The Child Mind Institute</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nctsn.org%2Fsites%2Fdefault%2Ffiles%2Fresources%2Ffact-sheet%2Fhelping_children_with_traumatic_separation_or_traumatic_grief_related_to_covid19.pdf&amp;token=%2BtKeKVQPKnOJZKQAnKh6F1dZBLADuxLarb5fCX5HrwoGGWjKNOTKRw4po6sYzsDi91T3mYjSaPHdBYXlUj4oVoNI2VBhvZdZEBSTBjP%2BQEc4nseLyyKpNJh1lQ%2F8P9SsPoN9uvzTTKv%2FM5Z4IN%2FSVQ%3D%3D&amp;TOPIC_ID=128389" target="_blank">The National Child Traumatic Stress Network</a></p><p></p><p>Preparing children and adolescents for the loss of a loved one is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/83707.html" rel="external">"Preparing children and adolescents for the loss of a parent or guardian"</a>.)</p><p class="headingAnchor" id="H3550242566"><span class="h1">IN-PERSON SCHOOL AND CHILD CARE</span><span class="headingEndMark"> — </span>The emergence and predominance of the highly transmissible variants (eg, Omicron [B.1.1.529]) warrant adherence to multiple mitigation measures to prevent school-related transmission, particularly among unvaccinated students and staff members [<a href="#rid253">253-257</a>]. In an observational study, after Massachusetts rescinded its statewide school masking requirement in February 2022, school districts that discontinued universal masking had a higher incidence of COVID-19 among students and staff than those that did not [<a href="#rid257">257</a>]. Additional measures may be necessary to prevent transmission between teachers/staff and from teachers/staff to household contacts [<a href="#rid258">258-261</a>].</p><p>A number of professional organizations provide guidance regarding in-person school and child care attendance, including the:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fabcsciencecollaborative.org%2F&amp;token=nY3M72EFR9vcuTLlK5CYVnyWia5nsnoEbHnvPkIeTi2KuNFYCrRuePWBQ4hufw7A&amp;TOPIC_ID=128389" target="_blank">ABC Science Collaborative</a>, developed by the Duke School of Medicine and the Duke Clinical Research Institute</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fcovid-19-planning-considerations-return-to-in-person-education-in-schools%2F&amp;token=guXoxXPZhzhQr3xSAS1LocRAKz4l9JRlZFGrzDjMG4LUlK4FClv4K1NcIrfDVfURQ2AUYfFNsVFe9U1l9urpo%2B1XUrZmUmXzPCn7euFeN3efDkSi%2Bnr4yK2Le6wgkla6rHLH3jYuUtP3z4%2B97%2Bvs7xj26E8JKXnjwNrARL0RSzY%3D&amp;TOPIC_ID=128389" target="_blank">American Academy of Pediatrics (AAP)</a> [<a href="#rid262">262</a>], which provides specific guidance on:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fcovid-19-and-safe-transportation-in-motor-vehicles%2F&amp;token=1K1WVsYMgCt270sBZytre%2BQlDrMXQwoAS6BWy3juL8XaCqyCiGFKmklX2XWazi3d7Xws9EMAIAf9l0OTu4iTSFOT4G73dKBRkfLxdHPminPFvzYnJR9w8xrbQdiXloPUI47wzi%2FbXxK8CPAfJ4GBX68AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=128389" target="_blank">Safe transportation in motor vehicles</a> [<a href="#rid263">263</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpages%2F2019-novel-coronavirus-covid-19-infections%2Fclinical-guidance%2Fguidance-related-to-childcare-during-covid-19%2F&amp;token=XLh1gQXbrfoS56d%2BZ2LL2YfosWh%2B1RwdMCoIe7kw24RXXL9GEB%2Fz34zw%2F3KPrVKCbWeZRxV7W%2BJ2u0CIXYxW9%2FwNDVOr%2FjkRBbW%2BHf2qJxTJYeR3SJpuY5KjfIbuOHv%2F95EnatMUfZ2j%2F45OJ9cfkg%3D%3D&amp;TOPIC_ID=128389" target="_blank">Child care</a> [<a href="#rid264">264</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcommunity%2Fschools-childcare%2Fk-12-childcare-guidance.html%3FCDC_AA_refVal%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fcoronavirus%252F2019-ncov%252Fcommunity%252Fschools-childcare%252Fk-12-guidance.html&amp;token=Acl9ETsqkfdqz%2BOMfDGXkPOLGilig5PYMFezPh5f%2FaxxtgXTXkSfHzyWkeL5Na4lTy7wHTVB%2B0KxAnGZI5Q0cePh%2FOeLxMwk9jyT1nx8%2B4BX3%2FF%2BOSI0RfnRQ0A6fJlIJcVx0rfqfhfYY8vprPgPzzeS%2FP1nuqY5qb8xBNM7LFsreZGFaFbn%2FGeCDQdae2bs&amp;TOPIC_ID=128389" target="_blank">The Centers for Disease Control and Prevention (CDC) operational guidance for K-12 schools and early care and education programs to support safe in-person learning</a> [<a href="#rid265">265</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbioethics.jhu.edu%2Fresearch-and-outreach%2Fprojects%2Feschool-initiative%2F&amp;token=XLpWpziYK8iLeOVVFFaSTZYtDFWEfE2irQwdE01b3gRXah4h5n5DkxxZFWzZw1b%2B8tZlGFd1eSHb%2FZBKhIwwxJh%2BMtI9ZtRYrx%2Fsq4uuzwc%3D&amp;TOPIC_ID=128389" target="_blank">The eSchool+ Initiative</a>, a cross-disciplinary collaboration from Johns Hopkins University</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nap.edu%2Fcatalog%2F25858%2Freopening-k-12-schools-during-the-covid-19-pandemic-prioritizing&amp;token=PdbtUgIi%2BFaBsCABz7TR5PhD%2FyyE4YoiOLOAEWgYuCjVrHK8z5z3myTtmIiGNonsY0xFRCIF063qO68vbhyIwpUZ8%2B3uSjHJCPi54AodOhz9AhVm7Yjks1LJTb5qVHNM&amp;TOPIC_ID=128389" target="_blank">National Academies of Sciences, Engineering, and Medicine</a> [<a href="#rid266">266</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpaarc.wustl.edu%2Fitems%2Fcovid-19-algorithms-for-schools%2F&amp;token=W1jmqqq8i%2FMKDgf%2FpFza2lYowE8E8I4nMV2TuRdwL3TgVFTN2dX7XYnMYtl0T%2B7sZii6PXov%2FDZSEl7XE5fSwmSlWFgXNQKFYLsikwo6%2FSE%3D&amp;TOPIC_ID=128389" target="_blank">Washington University Pediatric and Adolescent Ambulatory Research Consortium</a> [<a href="#rid267">267</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>World Health Organization (WHO) [<a href="#rid268">268</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fconsiderations-for-school-related-public-health-measures-in-the-context-of-covid-19&amp;token=SJBch2cFzwesSnGClyCivhaosstcc2%2Fwj0s6pWSSEBvuya%2BX8uhJ9lkmBAmvZXuElzepY3cdH9KwEYlngLFv7YzcS1avd0u3VIkONUVq7nT9BB7OBEENOLx5VrESfJqTJr%2FYT%2BgClCL1DojUJxxPXQ%3D%3D&amp;TOPIC_ID=128389" target="_blank">Considerations for school-related public health measures in context of COVID-19</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2F9789240017467&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h7bLDDnWC3XicBcpsIGU3t1e7boxHLUsG8tetzS5E5gVA%3D%3D&amp;TOPIC_ID=128389" target="_blank">Checklist to support schools re-opening and preparation for COVID-19 resurgences or similar public health crises</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Femergencies%2Fdiseases%2Fnovel-coronavirus-2019%2Fquestion-and-answers-hub%2Fq-a-detail%2Fcoronavirus-disease-covid-19-schools&amp;token=vhFT8L5egoaQP%2FCzWHB2APJtC3ozEu2JXiuWtmv5piM3AaFxmGWLwNYfuC28Uq2Q%2Bx%2Bl3NSUiCbXsy9THCJCG3u7xvN0MpmlH3W%2BaTv8LQ%2FXOrjAV%2B%2FXjro4ZYmyI4Xqv9rlCQPKWKPkJMrsn7ZSpQ%3D%3D&amp;TOPIC_ID=128389" target="_blank">Questions and answers</a></p><p></p><p>Key recommendations include [<a href="#rid262">262,265,266,268-271</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Promotion of vaccination for eligible staff and students [<a href="#rid272">272</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inclusion of multiple perspectives (eg, public health and infectious disease experts, educators, parents/caregivers, teachers, community leaders) and permits regional variation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Having training and safeguards in place (eg, protocols and necessary supplies and personnel for hand hygiene, face masks, cleaning, disinfection, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fcommunity%2Fschools-childcare%2Fventilation.html&amp;token=JtSDWmKYOndgv5WZTdoMOeQ76%2Bl48loBd4cC9joOj2ThU271ncs6AxICMr6BEYOsUOVj3UINqnEsP32QIfaZ6XdpB5kKZte1a7Ry9AIlVPzNJDsuvUyiEMsvXA%2FP79TN&amp;TOPIC_ID=128389" target="_blank">ventilation</a>, symptom screening, testing). Multilayered mitigation strategies are particularly important with widespread circulation of highly transmissible variants (eg, Delta [B.1.617.2], Omicron [B.1.1.529]) [<a href="#rid273">273</a>].</p><p></p><p class="bulletIndent1">In the school or child care setting, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwecandothis.hhs.gov%2Fresource%2Fupdated-cdc-masking-guidance&amp;token=aueAf9ezIMA5zjipTcoVnwC9MtUKj9uwPJn6zetWxTDoTYfEh0EwHevCs64bOD8ktEsIsTBgpdfpt12bqx0sEy0iAFSxoIrDoohhqPEIiYk%3D&amp;TOPIC_ID=128389" target="_blank">CDC</a> recommends that masks be worn indoors by all individuals ≥2 years of age, including those who are <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fvaccines%2Fstay-up-to-date.html&amp;token=rwhDrSIgnJnovjS7rLV2X8KfZNHNNE6i6pE%2BStb4Wnib4mOKSjIu4InwpimV0x7eprIS%2Bl2ogLO10QaTaikmY%2BoeZFfIjtBOl09zPWmXQKk%3D&amp;TOPIC_ID=128389" target="_blank">up to date with their COVID-19 vaccinations</a>, in areas where the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fyour-health%2Fcovid-by-county.html&amp;token=FDVED5iDTlE2%2BRmuCec5y0O2YA8uijEm7O9JCyFUvajEEvmijU9SVAaMi%2BJ6DxQPd4e4qQGZrGLG21NIHvW8V6NZIIak0h9DAZVVTlW2bqA%3D&amp;TOPIC_ID=128389" target="_blank">COVID-19 community level</a> is high [<a href="#rid164">164</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Establishing a protocol for monitoring and responding to changes in transmission in the school or community as well as children with COVID-19 symptoms or exposure [<a href="#rid265">265,267,269</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing realistic and practical mitigation strategies with flexibility to accommodate different types of students (eg, young children, those with developmental disabilities), classroom/school environments (eg, size, ventilation), and other factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consideration of the benefits and risks for all concerned parties (students, staff, parents/caregivers, community); the magnitude of benefits and risks may differ for students and teachers/staff. In addition to education, schools provide services to children with special health care needs, meals, opportunities to develop social/emotional skills, and physical activity. In a 2018 national survey, approximately 50 percent of adult teachers and adults living with school-aged children had conditions that are considered definite or possible risk factors for severe COVID-19 [<a href="#rid274">274</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Special considerations for vulnerable populations (eg, those with developmental challenges, those who are medically fragile or live in poverty) [<a href="#rid275">275</a>].</p><p></p><p>The eSchool+ Initiative provides a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fbioethics.jhu.edu%2Fresearch-and-outreach%2Fprojects%2Feschool-initiative%2Fschool-policy-tracker%2F&amp;token=jGeE1I2%2BrfE6LJZkaIs1dSuUe3crat9bWfOINc%2ByZN9UAMbR%2BBUoDRjN2jjHDKj9zL8HdZodf7SW%2FBEt%2FIG%2F0mv7%2Bt12Qn7%2BZ6f9KEPPE3%2BaS6qQgIM8uqoVLlH1e%2FeB&amp;TOPIC_ID=128389" target="_blank">tracker that categorizes school reopening plans</a> according to consideration of 12 categories (eg, core academics, SARS-CoV-2 protection, food and nutrition, caregiver choice, teacher and staff choice, children of poverty and disadvantage).</p><p class="headingAnchor" id="H1898476231"><span class="h1">SPORTS AND EXTRACURRICULAR ACTIVITIES</span><span class="headingEndMark"> — </span>Centers for Disease Control and Prevention (CDC) guidance recommends that individuals who live in areas with high <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fyour-health%2Fcovid-by-county.html&amp;token=FDVED5iDTlE2%2BRmuCec5y0O2YA8uijEm7O9JCyFUvajEEvmijU9SVAaMi%2BJ6DxQPd4e4qQGZrGLG21NIHvW8V6NZIIak0h9DAZVVTlW2bqA%3D&amp;TOPIC_ID=128389" target="_blank">COVID-19 community levels</a> wear a mask indoors in public [<a href="#rid162">162-164</a>]. In areas with moderate or low <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fyour-health%2Fcovid-by-county.html&amp;token=FDVED5iDTlE2%2BRmuCec5y0O2YA8uijEm7O9JCyFUvajEEvmijU9SVAaMi%2BJ6DxQPd4e4qQGZrGLG21NIHvW8V6NZIIak0h9DAZVVTlW2bqA%3D&amp;TOPIC_ID=128389" target="_blank">COVID-19 community levels</a>, children and adolescents should follow local regulations.</p><p>Decisions about participation in sports and extracurricular activities for children and adolescents should be made on a case-by-case basis and in accordance with local regulations and guidance [<a href="#rid159">159,269,276</a>]. Factors to consider include local disease activity, COVID-19 vaccination status, and other mitigation measures (eg, mask wearing, ventilation) and whether the activities increase the risk of transmission among students or staff (eg, by resulting in or requiring deep breathing [eg, intense exercise, shouting, singing]). Observational studies suggest that the risk of transmission is lower with outdoor than indoor sports activity [<a href="#rid277">277</a>]. Although indoor sports (eg, wrestling, gymnastics, ice hockey), close contact team sports, and intense exercise have been associated with increased transmission [<a href="#rid260">260,278-282</a>], there are reports of successful implementation of stringent mitigation protocols [<a href="#rid283">283</a>]. Social gatherings associated with team sports also may increase the risk of transmission [<a href="#rid276">276</a>].</p><p>Return to play or strenuous activity following infection is discussed separately  (<a class="graphic graphic_algorithm graphicRef134634" href="/z/d/graphic/134634.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/130803.html" rel="external">"COVID-19: Return to sport or strenuous activity following infection"</a>.)</p><p class="headingAnchor" id="H3891513958"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H499010559"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/127544.html" rel="external">"Patient education: COVID-19 and children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/126678.html" rel="external">"Patient education: COVID-19 overview (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/130329.html" rel="external">"Patient education: COVID-19 vaccines (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3951557328"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of severity</strong> – Children with COVID-19 and severe or critical lower respiratory tract disease generally require hospital admission. (See <a class="local">'Assessment of severity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe disease is defined by a new requirement for supplemental oxygen or increased requirement from baseline without new or increased need for ventilatory support (noninvasive or invasive).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Critical disease is defined by new or increased need for noninvasive or invasive mechanical ventilation, sepsis, multiorgan failure, or rapidly worsening clinical trajectory.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Supportive care (eg, respiratory support, fluid and electrolyte support, monitoring for cytokine release syndrome) is the mainstay of therapy for children with severe or critical COVID-19. (See <a class="local">'Supportive care for all patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of hospitalized children</strong> – We agree with recommendations from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fjpids%2Farticle%2F10%2F1%2F34%2F5904884&amp;token=djYKyj9M2WrCg90ff%2F0Y78uMNz3h7KRs0ax7Aq%2BgGcAzWJa2Yzt5jHZp%2FOlUhxNOJ0wbiifkiJnVqWfcvDvmaw%3D%3D&amp;TOPIC_ID=128389" target="_blank">multicenter interim guidance on the use of antiviral agents for children with COVID-19</a> and other experts that antiviral therapy should be considered on a case-by-case basis and preferably occur in the context of a clinical trial, if a clinical trial is available. (See <a class="local">'SARS-CoV-2 antiviral therapy for select patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decisions regarding antiviral therapy should be individualized according to disease severity, clinical trajectory, and underlying conditions that may increase the risk for progression.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When a decision is made to use antiviral therapy in a hospitalized child who cannot be enrolled in a clinical trial, we suggest <a class="drug drug_pediatric" data-topicid="127396" href="/z/d/drug information/127396.html" rel="external">remdesivir</a> rather than other antiviral agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Randomized trials in adults suggest a potential benefit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend not using <a class="drug drug_pediatric" data-topicid="13366" href="/z/d/drug information/13366.html" rel="external">hydroxychloroquine</a> or <a class="drug drug_pediatric" data-topicid="13147" href="/z/d/drug information/13147.html" rel="external">chloroquine</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Their emergency use authorization has been revoked, their clinical benefit is unproven, and they have potential toxicity.</p><p></p><p class="bulletIndent1">For hospitalized children who cannot be enrolled in a clinical trial, we make decisions about the use of adjunctive therapies for immune-mediated complications (eg, glucocorticoids, interleukin-6 inhibitors) of COVID-19 on a case-by-case basis. (See <a class="local">'Individualized adjunctive therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatient management</strong> – Children with documented or suspected COVID-19 and mild symptoms (eg, fever, cough, pharyngitis, other respiratory symptoms) generally should be managed at home unless they have a chronic condition that increases their risk of severe disease. Decisions regarding outpatient antiviral therapy are made on a case-by-case basis  (<a class="graphic graphic_table graphicRef139078" href="/z/d/graphic/139078.html" rel="external">table 3</a>). Additional management is focused on prevention of transmission to others (ie, isolation), monitoring for clinical deterioration (eg, difficulty breathing, cyanosis, symptoms of shock), and supportive care. (See <a class="local">'Outpatient therapy for select children'</a> above and <a class="local">'Symptomatic and supportive care'</a> above.)</p><p></p><p class="bulletIndent1">Symptomatic care for COVID-19 in the outpatient setting is similar to that for other upper respiratory or gastrointestinal clinical syndromes. It is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16629.html" rel="external">"The common cold in children: Management and prevention", section on 'Symptomatic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/2875.html" rel="external">"Acute pharyngitis in children and adolescents: Symptomatic treatment", section on 'Symptomatic treatment'</a> and  <a class="medical medical_review" href="/z/d/html/5989.html" rel="external">"Fever in infants and children: Pathophysiology and management", section on 'Management of fever'</a> and  <a class="medical medical_review" href="/z/d/html/5992.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Management and prevention", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1">Prevention of transmission focuses on isolation, hygiene, and masking. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fif-you-are-sick%2Findex.html%23%3A%7E%3Atext%3DContact%2520a%2520healthcare%2520provider%2520right%2Cfew%2520days%2520to%2520be%2520effective&amp;token=Otj5%2BXBGO9DNYRUZT8OMyvL50C%2B33Tzsc%2FlaVHEgUxnXaBwdTZON9f9MCucbDLcSyxTV9kEicNOcvapLgqS4WQVANXhq%2Fo%2B7g27KRvHwHJQiQCHD3NhQCgnDy7Rh4Wd6GIm6KMKUWfQv%2Fqu%2FtLefCsYFYEAM466e1KQHaNYGHDTCBOojiKpUDQQHZpC03YQ%2B&amp;TOPIC_ID=128389" target="_blank">Centers for Disease Control and Prevention</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fhome-care-for-patients-with-suspected-novel-coronavirus-%28ncov%29-infection-presenting-with-mild-symptoms-and-management-of-contacts&amp;token=JuUD9LLbWAI%2FZfQMeccrsf4%2BXrNnpt%2F7JgqmfsdlOdSiE2FwmZQx5IYUDqkOxMAaFfjAAyKBFLZobbHKPzJm1dAlqnGMEC3CWm1Hi13n14BxWR1CYSGeFwiYOuYDX2xr66liAeECeQOJNnXK77xqKvlZFCExDwXxpuBlbv1Y%2FTqvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=128389" target="_blank">World Health Organization</a> provide guidance about preventing transmission of COVID-19 in the home and outpatient setting. (See <a class="local">'Prevention of transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pre-exposure prophylaxis</strong> – SARS-CoV-2 immunization is the only method of pre-exposure prophylaxis for eligible individuals. Pre-exposure prophylaxis with copackaged <a class="drug drug_pediatric" data-topicid="134628" href="/z/d/drug information/134628.html" rel="external">tixagevimab-cilgavimab</a> is no longer authorized because it is unlikely to be active against circulating variants. (See <a class="local">'Pre-exposure prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of indirect effects</strong> – Management of COVID-19 in children also encompasses management of indirect effects, particularly adverse physical and mental health effects of prolonged home confinement (eg, decreased physical activity, poorer quality diet, social isolation, increased risk of violence). (See <a class="local">'Addressing or mitigating indirect effects of the pandemic'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. J Pediatric Infect Dis Soc 2021; 10:34.</a></li><li class="breakAll">National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. covid19treatmentguidelines.nih.gov/ (Accessed on March 06, 2023).</li><li class="breakAll">European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19 (Accessed on March 19, 2020).</li><li class="breakAll">WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 https://www.who.int/publications-detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 (Accessed on April 21, 2020).</li><li class="breakAll">https://dgs-urgent.sante.gouv.fr/dgsurgent/inter/detailsMessageBuilder.do?id=30500&amp;cmd=visualiserMessage (Accessed on March 19, 2020).</li><li><a class="nounderline abstract_t">Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368:m1086.</a></li><li><a class="nounderline abstract_t">Prada L, D Santos C, Baião RA, et al. Risk of SARS-CoV-2 Infection and COVID-19 Severity Associated With Exposure to Nonsteroidal Anti-Inflammatory Drugs: Systematic Review and Meta-Analysis. J Clin Pharmacol 2021; 61:1521.</a></li><li><a class="nounderline abstract_t">South AM, Brady TM, Flynn JT. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective. Hypertension 2020; 76:16.</a></li><li class="breakAll">Statement from the American Heart Association, the Heart Failure Society of America and the American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician (Accessed on March 18, 2020).</li><li class="breakAll">International Society of Hypertension. A statement from the International Society of Hypertension on COVID-19. https://ish-world.com/news/a/A-statement-from-the-International-Society-of-Hypertension-on-COVID-19/ (Accessed on March 18, 2020).</li><li class="breakAll">Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (Accessed on March 18, 2020).</li><li class="breakAll">Hypertension Canada. Hypertension Canada’s Statement on: Hypertension, ACE-Inhibitors and Angiotensin Receptor Blockers and COVID-19. https://hypertension.ca/wp-content/uploads/2020/03/2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf (Accessed on March 18, 2020).</li><li class="breakAll">European Society of Hypertension. ESH Statement on COVID-19. Available at: https://www.eshonline.org/spotlights/update-on-covid-19/ (Accessed on July 16, 2020).</li><li><a class="nounderline abstract_t">Marlais M, Wlodkowski T, Vivarelli M, et al. The severity of COVID-19 in children on immunosuppressive medication. Lancet Child Adolesc Health 2020; 4:e17.</a></li><li><a class="nounderline abstract_t">Turner D, Huang Y, Martín-de-Carpi J, et al. COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr 2020.</a></li><li><a class="nounderline abstract_t">Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.</a></li><li><a class="nounderline abstract_t">Fishman JA. Infection in Organ Transplantation. Am J Transplant 2017; 17:856.</a></li><li class="breakAll">Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Version 10.2.0. Last updated March 1, 2023. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ (Accessed on March 05, 2023).</li><li><a class="nounderline abstract_t">Larson DT, Sherner JH, Gallagher KM, et al. Clinical Outcomes of Coronavirus Disease 2019 With Evidence-based Supportive Care. Clin Infect Dis 2022; 74:133.</a></li><li><a class="nounderline abstract_t">Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med 2020; 383:1757.</a></li><li><a class="nounderline abstract_t">Calderon M, Gysin G, Gujjar A, et al. Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis 2023; 23:14.</a></li><li><a class="nounderline abstract_t">Moffitt KL, Nakamura MM, Young CC, et al. Community-onset bacterial coinfection in children critically ill with SARS-cov-2 infection. Open Forum Infect Dis 2023; :Online first.</a></li><li><a class="nounderline abstract_t">Goldenberg NA, Sochet A, Albisetti M, et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness. J Thromb Haemost 2020; 18:3099.</a></li><li><a class="nounderline abstract_t">Barnes GD, Burnett A, Allen A, et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum. J Thromb Thrombolysis 2022; 54:197.</a></li><li><a class="nounderline abstract_t">Whitworth H, Sartain SE, Kumar R, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood 2021; 138:190.</a></li><li><a class="nounderline abstract_t">Aguilera-Alonso D, Murias S, Martínez-de-Azagra Garde A, et al. Prevalence of thrombotic complications in children with SARS-CoV-2. Arch Dis Child 2021; 106:1129.</a></li><li><a class="nounderline abstract_t">Wang Z, Zhao S, Tang Y, et al. Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review. Eur J Pediatr 2022; 181:2135.</a></li><li><a class="nounderline abstract_t">Campbell JI, Ocwieja KE, Nakamura MM. A Call for Pediatric COVID-19 Clinical Trials. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; 382:2327.</a></li><li><a class="nounderline abstract_t">Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020; 382:1787.</a></li><li><a class="nounderline abstract_t">WHO Solidarity Trial Consortium, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384:497.</a></li><li><a class="nounderline abstract_t">Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269.</a></li><li><a class="nounderline abstract_t">Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9.</a></li><li><a class="nounderline abstract_t">de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020; 117:6771.</a></li><li class="breakAll">Health Canada. Summary Safety Review - Veklury (remdesivir). https://covid-vaccine.canada.ca/info/summary-safety-review-detail.html?linkID=SSR00271&amp;wbdisable=true (Accessed on August 20, 2021).</li><li><a class="nounderline abstract_t">Mulangu S, Dodd LE, Davey RT Jr, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med 2019; 381:2293.</a></li><li class="breakAll">World Health Organization (WHO). WHO R&amp;D Blueprint – Ad-hoc expert consultation on clinical trials for Ebola therapeutics, October 2018. Available at: https://www.who.int/ebola/drc-2018/treatments-approved-for-compassionate-use-update/en/ (Accessed on May 06, 2020).</li><li><a class="nounderline abstract_t">Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020; 383:1813.</a></li><li><a class="nounderline abstract_t">Garibaldi BT, Wang K, Robinson ML, et al. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. JAMA Netw Open 2021; 4:e213071.</a></li><li><a class="nounderline abstract_t">Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2022; 22:209.</a></li><li><a class="nounderline abstract_t">Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Update Alert: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med 2021; 174:W66.</a></li><li><a class="nounderline abstract_t">Mozaffari E, Chandak A, Zhang Z, et al. Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. Clin Infect Dis 2022; 75:e450.</a></li><li><a class="nounderline abstract_t">Kaka AS, MacDonald R, Linskens EJ, Wilt TJ. Update Alert 2: Remdesivir for Adults With COVID-19. Ann Intern Med 2021; 174:W114.</a></li><li><a class="nounderline abstract_t">Kaka AS, MacDonald R, Linskens EJ, et al. Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points. Ann Intern Med 2022; 175:701.</a></li><li><a class="nounderline abstract_t">Correction: Remdesivir for Adults With COVID-19. Ann Intern Med 2022; 175:458.</a></li><li><a class="nounderline abstract_t">WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet 2022; 399:1941.</a></li><li><a class="nounderline abstract_t">Ansems K, Grundeis F, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8:CD014962.</a></li><li><a class="nounderline abstract_t">Liu E, Smyth RL, Li Q, et al. Guidelines for the prevention and management of children and adolescents with COVID-19. Eur J Pediatr 2022; 181:4019.</a></li><li class="breakAll">Coronavirus (COVID-19) update: FDA approves first COVID-19 treatment for young children. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-approves-first-covid-19-treatment-young-children (Accessed on April 26, 2022).</li><li class="breakAll">US FDA product information Veklury (remdesivir) injection. US Food and Drug Administration (FDA) approved product information. Revised September, 2022. US National Library of Medicine. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214787s014lbl.pdf (Accessed on October 20, 2022).</li><li><a class="nounderline abstract_t">Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020; 383:1827.</a></li><li><a class="nounderline abstract_t">Goldman DL, Aldrich ML, Hagmann SHF, et al. Compassionate Use of Remdesivir in Children With Severe COVID-19. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Chow EJ, Maust B, Kazmier KM, Stokes C. Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature. J Pediatric Infect Dis Soc 2021; 10:926.</a></li><li><a class="nounderline abstract_t">Sanchez-Codez MI, Rodriguez-Gonzalez M, Gutierrez-Rosa I. Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection. Eur J Pediatr 2021; 180:1627.</a></li><li><a class="nounderline abstract_t">Eleftheriou I, Liaska M, Krepis P, et al. Sinus Bradycardia in Children Treated With Remdesivir for COVID-19. Pediatr Infect Dis J 2021; 40:e356.</a></li><li><a class="nounderline abstract_t">Rau C, Apostolidou S, Singer D, et al. Remdesivir, Sinus Bradycardia and Therapeutic Drug Monitoring in Children With Severe COVID-19. Pediatr Infect Dis J 2021; 40:e528.</a></li><li class="breakAll">ClinicalTrials.gov. Study to evaluate the safety, tolerability, and efficacy of remdesivir (GS-5734) in participants from birth to &lt;18 years with coronavirus disease (2019) (COVID-19) (CARAVAN). https://www.clinicaltrials.gov/ct2/show/NCT04431453 (Accessed on April 26, 2022).</li><li><a class="nounderline abstract_t">Rubin R. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment. JAMA 2022; 327:2281.</a></li><li class="breakAll">Fact sheet for healthcare providers: Emergency use authorization (EUA) of baricitinib. https://www.fda.gov/media/143823/download (Accessed on June 27, 2022).</li><li><a class="nounderline abstract_t">Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 2021; 384:795.</a></li><li><a class="nounderline abstract_t">Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021; 9:1407.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet 2022; 400:359.</a></li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group, Horby P, Mafham M, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020; 383:2030.</a></li><li><a class="nounderline abstract_t">Hernandez AV, Roman YM, Pasupuleti V, et al. Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. Ann Intern Med 2020; 173:W156.</a></li><li><a class="nounderline abstract_t">Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med 2020; 383:2041.</a></li><li><a class="nounderline abstract_t">Perez J, Roustit M, Lepelley M, et al. Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic. Ann Intern Med 2021; 174:878.</a></li><li><a class="nounderline abstract_t">Fiolet T, Guihur A, Rebeaud ME, et al. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect 2021; 27:19.</a></li><li><a class="nounderline abstract_t">Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 2020; 323:1824.</a></li><li class="breakAll">US Food and Drug Administration (FDA). FDA News Release. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and (Accessed on June 15, 2020).</li><li class="breakAll">World Health Organization. Therapeutics and COVID-19: living guideline. January 13, 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.1 (Accessed on January 26, 2023).</li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020; 396:1345.</a></li><li><a class="nounderline abstract_t">Dulek DE, Fuhlbrigge RC, Tribble AC, et al. Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. J Pediatric Infect Dis Soc 2020; 9:716.</a></li><li><a class="nounderline abstract_t">WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020; 324:1330.</a></li><li><a class="nounderline abstract_t">Agarwal A, Hunt B, Stegemann M, et al. A living WHO guideline on drugs for covid-19. BMJ 2020; 370:m3379.</a></li><li><a class="nounderline abstract_t">Update to living WHO guideline on drugs for covid-19. BMJ 2023; 380:57.</a></li><li class="breakAll">World Health Organization. Corticosteroids for COVID-19. Living guidance. September 2, 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 (Accessed on September 04, 2020).</li><li><a class="nounderline abstract_t">Huang CW, Yu AS, Song H, et al. Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality. JAMA Netw Open 2022; 5:e221455.</a></li><li class="breakAll">Randomized evaluation of COVID-19 therapy (RECOVERY) study protocol. https://www.recoverytrial.net/ (Accessed on September 15, 2020).</li><li><a class="nounderline abstract_t">RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021; 384:693.</a></li><li><a class="nounderline abstract_t">Dequin PF, Heming N, Meziani F, et al. Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2020; 324:1298.</a></li><li><a class="nounderline abstract_t">Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020; 324:1307.</a></li><li><a class="nounderline abstract_t">Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020; 324:1317.</a></li><li><a class="nounderline abstract_t">Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev 2021; 8:CD014963.</a></li><li class="breakAll">Actemra (tocilizumab) injection. US Food and Drug Administration (FDA) approved product information. Revised December 2022. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125472s049lbl.pdf (Accessed on January 09, 2023).</li><li class="breakAll">Fact sheet for healthcare providers. Emergency use authorization for actemra (tocilizumab). https://www.fda.gov/media/150321/download (Accessed on January 09, 2023).</li><li><a class="nounderline abstract_t">Teoh Z, Danziger-Isakov L, Courter JD, et al. Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. Pediatr Infect Dis J 2023; 42:119.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Somers EC, Eschenauer GA, Troost JP, et al. Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. Clin Infect Dis 2021; 73:e445.</a></li><li><a class="nounderline abstract_t">Hall MW, Joshi I, Leal L, Ooi EE. Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention. Clin Infect Dis 2022; 74:144.</a></li><li><a class="nounderline abstract_t">Ye Z, Rochwerg B, Wang Y, et al. Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. CMAJ 2020; 192:E536.</a></li><li><a class="nounderline abstract_t">Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211:80.</a></li><li><a class="nounderline abstract_t">Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020; 7:CD013600.</a></li><li><a class="nounderline abstract_t">Siemieniuk RA, Bartoszko JJ, Zeraatkar D, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 2020; 370:m2980.</a></li><li><a class="nounderline abstract_t">Update to living systematic review on drug treatments for covid-19. BMJ 2020; 371:m4852.</a></li><li><a class="nounderline abstract_t">Update to living systematic review on drug treatments for covid-19. BMJ 2021; 372:n858.</a></li><li><a class="nounderline abstract_t">Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA 2021; 325:1185.</a></li><li><a class="nounderline abstract_t">Arrieta A, Galvis AE, Morphew T, et al. Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients. Pediatr Infect Dis J 2021; 40:606.</a></li><li><a class="nounderline abstract_t">Focosi D, Franchini M, Tuccori M, Cruciani M. Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review. Vaccines (Basel) 2022; 10.</a></li><li><a class="nounderline abstract_t">Hussey GD, Klein M. A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323:160.</a></li><li class="breakAll">World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts. Interim guidance. August 13, 2020. https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts (Accessed on August 25, 2020).</li><li class="breakAll">United States Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19). If you are sick or caring for someone. Available at: https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html (Accessed on November 30, 2022).</li><li class="breakAll">United States Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: Information for healthcare providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html (Accessed on February 22, 2023).</li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19.COVID-19 Interim Guidance. Management Strategies in Children and Adolescents with Mild to Moderate COVID-19. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/outpatient-covid-19-management-strategies-in-children-and-adolescents/ (Accessed on February 21, 2023).</li><li><a class="nounderline abstract_t">Wolf J, Abzug MJ, Anosike BI, et al. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. J Pediatric Infect Dis Soc 2022; 11:177.</a></li><li class="breakAll">US Food and Drug Administration. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the omicron variant. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron (Accessed on January 25, 2022).</li><li class="breakAll">US Department of Health and Human Safety. COVID-19 therapeutics. Update - Allocation of balmanivimab/etesevimab and REGEN-COV therapeutics paused. https://aspr.hhs.gov/COVID-19/Therapeutics/Pages/default.aspx (Accessed on February 01, 2022).</li><li class="breakAll">US Food and Drug Administration. FDA updates sotrovimab emergency use authorization. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization (Accessed on April 05, 2022).</li><li class="breakAll">US Food and Drug Administration. FDA Announces bebtelovimab is not currently authorized in any US region. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region (Accessed on December 02, 2022).</li><li class="breakAll">United States Centers for Disease Control and Prevention. COVID Data Tracker. Available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions (Accessed on February 23, 2023).</li><li class="breakAll">National Institutes of Health. COVID-19 Treatment Guidelines. Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment and Prevention of COVID-19 When There Are Logistical or Supply Constraints. Last updated March 24, 2022. https://www.covid19treatmentguidelines.nih.gov/overview/prioritization-of-therapeutics/ (Accessed on January 12, 2023).</li><li><a class="nounderline abstract_t">Imai M, Ito M, Kiso M, et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N Engl J Med 2023; 388:89.</a></li><li class="breakAll">Fact sheet for healthcare providers: Emergency use authorization for paxlovid. https://www.fda.gov/media/155050/download (Accessed on February 01, 2023).</li><li><a class="nounderline abstract_t">Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022; 386:1397.</a></li><li><a class="nounderline abstract_t">Pitre T, Van Alstine R, Chick G, et al. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis. CMAJ 2022; 194:E969.</a></li><li><a class="nounderline abstract_t">Lai CC, Wang YH, Chen KH, et al. The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Viruses 2022; 14.</a></li><li><a class="nounderline abstract_t">Reis S, Metzendorf MI, Kuehn R, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst Rev 2022; 9:CD015395.</a></li><li><a class="nounderline abstract_t">Vora SB, Englund JA, Trehan I, et al. Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients. Pediatr Infect Dis J 2023; 42:32.</a></li><li class="breakAll">Institute for Safe Medication Practices. Numerous wrong dose errors with paxlovid. https://www.ismp.org/resources/numerous-wrong-dose-errors-paxlovid (Accessed on July 20, 2022).</li><li class="breakAll">US Food and Drug Administration. FDA updates on paxlovid for health care providers. https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers (Accessed on May 18, 2022).</li><li class="breakAll">Paxlovid patient eligibility screening checklist tool for prescribers. https://www.fda.gov/media/158165/download (Accessed on August 30, 2022).</li><li class="breakAll">Infectious Diseases Society of America. Management of drug interactions with nirmatrelvir/ritonavir (paxlovid): Resource for clinicians. Last updated May 6, 2022 -- Version 1.1. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/management-of-drug-interactions-with-nirmatrelvirritonavir-paxlovid/ (Accessed on May 09, 2022).</li><li class="breakAll">United States Centers for Disease Control and Prevention. COVID-19 rebound after paxlovid treatment. Available at: https://emergency.cdc.gov/han/2022/han00467.asp (Accessed on June 01, 2022).</li><li><a class="nounderline abstract_t">Zheng Q, Ma P, Wang M, et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect 2023; 86:66.</a></li><li><a class="nounderline abstract_t">Smith DM, Li JZ, Moser C, et al. Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19. JAMA Netw Open 2022; 5:e2238867.</a></li><li><a class="nounderline abstract_t">Pandit JA, Radin JM, Chiang DC, et al. The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls. Clin Infect Dis 2023; 77:25.</a></li><li><a class="nounderline abstract_t">Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med 2022; 386:305.</a></li><li class="breakAll">Fact sheet for healthcare providers: Emergency use authorization for molnupiravir. https://www.fda.gov/media/155054/download (Accessed on February 23, 2023).</li><li><a class="nounderline abstract_t">Meltzer DO, Best TJ, Zhang H, et al. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open 2020; 3:e2019722.</a></li><li><a class="nounderline abstract_t">Murai IH, Fernandes AL, Sales LP, et al. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA 2021; 325:1053.</a></li><li><a class="nounderline abstract_t">Jolliffe DA, Holt H, Greenig M, et al. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). BMJ 2022; 378:e071230.</a></li><li><a class="nounderline abstract_t">Brunvoll SH, Nygaard AB, Ellingjord-Dale M, et al. Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial. BMJ 2022; 378:e071245.</a></li><li><a class="nounderline abstract_t">Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. BMJ 2020; 368:m1182.</a></li><li class="breakAll">World Health Organization. Living guidance for clinical management of COVID-19. January 13, 2023. https://www.who.int/teams/health-care-readiness/covid-19 (Accessed on January 26, 2023).</li><li><a class="nounderline abstract_t">Oldenburg CE, Pinsky BA, Brogdon J, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA 2021; 326:490.</a></li><li><a class="nounderline abstract_t">PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet 2021; 397:1063.</a></li><li><a class="nounderline abstract_t">Kashour Z, Riaz M, Garbati MA, et al. Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. J Antimicrob Chemother 2021; 76:30.</a></li><li><a class="nounderline abstract_t">Bramante CT, Huling JD, Tignanelli CJ, et al. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med 2022; 387:599.</a></li><li><a class="nounderline abstract_t">Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev 2021; 7:CD015017.</a></li><li><a class="nounderline abstract_t">McCarthy MW, Naggie S, Boulware DR, et al. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA 2023; 329:296.</a></li><li class="breakAll">United States Food and Drug Administration. Ivermectin intended for animals: Letter to stakeholders - Do not use in humans as a treatment for COVID-19. Available at: www.fda.gov/safety/medical-product-safety-information/ivermectin-intended-animals-letter-stakeholders-do-not-use-humans-treatment-covid-19 (Accessed on April 13, 2020).</li><li class="breakAll">US Food and Drug Administration. Why you should not use ivermectin to treat or prevent COVID-19. https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19 (Accessed on October 26, 2021).</li><li class="breakAll">Centers for Disease Control and Prevention. Health alert network. Rapid increase in ivermectin prescriptions and reports of severe illness associated with use of products containing ivermectin to prevent or treat COVID-19. https://emergency.cdc.gov/han/2021/han00449.asp (Accessed on August 27, 2021).</li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19. COVID-19 interim guidance. Post-COVID-19 conditions in children and adolescents. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/post-covid-19-conditions-in-children-and-adolescents/ (Accessed on October 06, 2022).</li><li><a class="nounderline abstract_t">Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes &gt;30 Days After SARS-CoV-2 Infection Among Persons Aged &lt;18 Years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep 2022; 71:59.</a></li><li><a class="nounderline abstract_t">Salmi H, Heinonen S, Hästbacka J, et al. New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic. Arch Dis Child 2022; 107:180.</a></li><li><a class="nounderline abstract_t">Hernandez-Romieu AC, Carton TW, Saydah S, et al. Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2. JAMA Netw Open 2022; 5:e2147053.</a></li><li><a class="nounderline abstract_t">Gottesman BL, Yu J, Tanaka C, et al. Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic. JAMA Pediatr 2022; 176:414.</a></li><li><a class="nounderline abstract_t">Unsworth R, Wallace S, Oliver NS, et al. New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K. Diabetes Care 2020; 43:e170.</a></li><li><a class="nounderline abstract_t">Magge SN, Wolf RM, Pyle L, et al. The Coronavirus Disease 2019 Pandemic is Associated with a Substantial Rise in Frequency and Severity of Presentation of Youth-Onset Type 2 Diabetes. J Pediatr 2022; 251:51.</a></li><li><a class="nounderline abstract_t">Kendall EK, Olaker VR, Kaelber DC, et al. Association of SARS-CoV-2 Infection With New-Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021. JAMA Netw Open 2022; 5:e2233014.</a></li><li><a class="nounderline abstract_t">Rewers M, Bonifacio E, Ewald D, et al. SARS-CoV-2 Infections and Presymptomatic Type 1 Diabetes Autoimmunity in Children and Adolescents From Colorado, USA, and Bavaria, Germany. JAMA 2022; 328:1252.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. COVID-19. Post-COVID conditions: Information for healthcare providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-index.html (Accessed on January 12, 2023).</li><li><a class="nounderline abstract_t">Lewis D. Long COVID and kids: scientists race to find answers. Nature 2021; 595:482.</a></li><li><a class="nounderline abstract_t">Kikkenborg Berg S, Dam Nielsen S, Nygaard U, et al. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health 2022; 6:240.</a></li><li><a class="nounderline abstract_t">Stephenson T, Pinto Pereira SM, Shafran R, et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. Lancet Child Adolesc Health 2022; 6:230.</a></li><li><a class="nounderline abstract_t">Zimmermann P, Pittet LF, Curtis N. The Challenge of Studying Long COVID: An Updated Review. Pediatr Infect Dis J 2022; 41:424.</a></li><li><a class="nounderline abstract_t">Pinto Pereira SM, Shafran R, Nugawela MD, et al. Natural course of health and well-being in non-hospitalised children and young people after testing for SARS-CoV-2: a prospective follow-up study over 12 months. Lancet Reg Health Eur 2023; 25:100554.</a></li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19. COVID-19 Interim Guidance. Interim guidance on supporting the emotional and behavioral health needs of children, adolescents, and families during the COVID-19 pandemic. Available at: services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-on-supporting-the-emotional-and-behavioral-health-needs-of-children-adolescents-and-families-during-the-covid-19-pandemic/ (Accessed on September 14, 2022).</li><li class="breakAll">American Academy of Pediatric. COVID-19 interim guidance: Return to sports and physical activity. Available at: https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-interim-guidance-return-to-sports/ (Accessed on October 06, 2022).</li><li><a class="nounderline abstract_t">Massetti GM, Jackson BR, Brooks JT, et al. Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1057.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. COVID-19. How to protect yourself and others. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html (Accessed on February 23, 2023).</li><li class="breakAll">United States Centers for Disease Control and Prevention. Frequently Asked Questions about COVID-19 vaccination. After your vaccine. Do I need to wear a mask and avoid close contect with others if I am fully vaccinated? https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html (Accessed on February 23, 2023).</li><li class="breakAll">United States Centers for Disease Control and Prevention.  COVID-19. Use and care of masks. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/about-face-coverings.html (Accessed on May 11, 2023).</li><li class="breakAll">United States Centers for Disease Control and Prevention. COVID-19. COVID-19 by county. https://www.cdc.gov/coronavirus/2019-ncov/your-health/covid-by-county.html (Accessed on August 12, 2022).</li><li class="breakAll">World Health Organization. Roadmap to improve and ensure good indoor ventilation in the context of COVID-19. March 1, 2021. https://www.who.int/publications/i/item/9789240021280 (Accessed on March 11, 2021).</li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19, COVID-19 Interim Guidance, Face Masks and Other Prevention Strategies. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/face-masks-and-other-prevention-strategies/ (Accessed on June 30, 2023).</li><li class="breakAll">American Academy of Pediatrics. Critical updates on COVID-19. Clinical guidance. Guidance on Providing Pediatric Well-Care During COVID-19. services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/guidance-on-providing-pediatric-well-care-during-covid-19/ (Accessed on November 03, 2022).</li><li class="breakAll">American Academy of Pediatrics. Guidance on newborn screening during COVID-19. Available at: services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/guidance-on-newborn-screening-during-covid-19/ (Accessed on October 23, 2020).</li><li class="breakAll">Sparrow C, Benjamin E, Schwarz D, et al. Keeping kids out of the clinic who don't need to be there.  Available at: www.ariadnelabs.org/resources/articles/news/keeping-kids-out-of-the-clinic-who-dont-need-to-be-there/ (Accessed on March 30, 2020).</li><li><a class="nounderline abstract_t">Curfman AL, Hackell JM, Herendeen NE, et al. Telehealth: Improving Access to and Quality of Pediatric Health Care. Pediatrics 2021; 148.</a></li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19. COVID-19 Interim Guidance. Providing Acute Care in the Ambulatory Setting During the COVID-19 Pandemic. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/caring-for-children-with-acute-illness-in-the-ambulatory-care-setting-during-the-public-health-emergency/ (Accessed on February 21, 2023).</li><li class="breakAll">United States Centers for Disease Control and Prevention. COVID-19. Understanding risk. Available at: https://www.cdc.gov/coronavirus/2019-ncov/your-health/understanding-risk.html (Accessed on August 23, 2022).</li><li><a class="nounderline abstract_t">Honein MA, Christie A, Rose DA, et al. Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1860.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. COVID-19. Types of masks and respirators. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/types-of-masks.html (Accessed on January 25, 2022).</li><li class="breakAll">World Health Organization. Infection prevention and control in the context of coronavirus disease (COVID-19): A living guideline. January 13, 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-ipc-guideline-2023.1 (Accessed on January 19, 2023).</li><li class="breakAll">US Food and Drug Administration. Q &amp; A for consumers: Hand sanitizers and COVID-19. Available at: www.fda.gov/drugs/information-drug-class/qa-consumers-hand-sanitizers-and-covid-19 (Accessed on March 08, 2022).</li><li class="breakAll">US Food and Drug Administration. Drug safety communication. FDA warns that vapors from alcohol-based hand sanitizers can have side effects. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-vapors-alcohol-based-hand-sanitizers-can-have-side-effects (Accessed on June 22, 2021).</li><li class="breakAll">US Food and Drug Administration. FDA warns that getting alcohol-based hand sanitizer in the eyes can cause serious injury. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-getting-alcohol-based-hand-sanitizer-eyes-can-cause-serious-injury (Accessed on November 02, 2021).</li><li class="breakAll">US Food and Drug Administration (FDA) news release. Coronavirus (COVID-19) update: FDA continues to ensure availability of alcohol-based hand sanitizer during the COVID-19 pandemic, addresses safety concerns. Available at: www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-ensure-availability-alcohol-based-hand-sanitizer-during (Accessed on April 29, 2020).</li><li class="breakAll">American Academy of Pediatrics. Hand Sanitizers: Keep Children Safe from Poisoning Risk. Available at: www.healthychildren.org/English/safety-prevention/at-home/Pages/Keep-Hand-Sanitizer-Out-of-Childrens-Reach.aspx (Accessed on September 15, 2020).</li><li class="breakAll">US Food and Drug Administration. FDA updates on hand sanitizers consumers should not use. Available at: www.fda.gov/drugs/drug-safety-and-availability/fda-updates-hand-sanitzers-methanol?deliveryName=USCDC_511-DM32445 (Accessed on February 23, 2023).</li><li><a class="nounderline abstract_t">Yip L, Bixler D, Brooks DE, et al. Serious Adverse Health Events, Including Death, Associated with Ingesting Alcohol-Based Hand Sanitizers Containing Methanol - Arizona and New Mexico, May-June 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1070.</a></li><li class="breakAll">US Food and Drug Administration. FDA news release. Coronavirus (COVID-19) Update: FDA takes action to place all alcohol-based hand sanitizers from Mexico on import alert to help prevent entry of violative and potentially dangerous products into US, protect US consumers. www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-place-all-alcohol-based-hand-sanitizers-mexico-import (Accessed on January 28, 2021).</li><li><a class="nounderline abstract_t">Martin GC, Le Roux G, Guindolet D, et al. Pediatric Eye Injuries by Hydroalcoholic Gel in the Context of the Coronavirus Disease 2019 Pandemic. JAMA Ophthalmol 2021; 139:348.</a></li><li><a class="nounderline abstract_t">Yangzes S, Grewal S, Gailson T, Grewal SPS. Hand Sanitizer-Induced Ocular Injury: A COVID-19 Hazard in Children. JAMA Ophthalmol 2021; 139:362.</a></li><li><a class="nounderline abstract_t">Au SCL. Hand sanitizer associated ocular chemical injury: A mini-review on its rise under COVID-19. Vis J Emerg Med 2020; 21:100881.</a></li><li class="breakAll">US Food and Drug Administration. FDA announces Evusheld is not currently authorized for emergency use in the U.S. https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us (Accessed on January 26, 2023).</li><li class="breakAll">Fact sheet for health care providers. Emergency use authorization (EUA) of bamlanivimab and etesevimab. https://www.fda.gov/media/145802/download (Accessed on January 24, 2022).</li><li class="breakAll">Fact sheet for health care providers. Emergency use authorization (EUA) of casirivimab and imdevimab. https://www.fda.gov/media/145611/download (Accessed on January 25, 2022).</li><li><a class="nounderline abstract_t">Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med 2020; 383:517.</a></li><li><a class="nounderline abstract_t">Barnabas RV, Brown ER, Bershteyn A, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. Ann Intern Med 2021; 174:344.</a></li><li><a class="nounderline abstract_t">Mitjà O, Corbacho-Monné M, Ubals M, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med 2021; 384:417.</a></li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19. Clinical Guidance. Caring for Children and Youth With Special Health Care Needs During the COVID-19 Pandemic. services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/caring-for-children-and-youth-with-special-health-care-needs-during-the-covid-19-pandemic/ (Accessed on March 02, 2022).</li><li class="breakAll">Davidson LF, Kuo DZ. What to do when school closures interrupt services outlined in IEPs. AAP News June 10,2020. Available at: www.aappublications.org/news/2020/06/10/covid19cyshcn061120 (Accessed on June 16, 2020).</li><li><a class="nounderline abstract_t">Kelly MM, DeMuri GP, Barton HJ, et al. Priorities for Safer In-Person School for Children With Medical Complexity During COVID-19. Pediatrics 2022; 149.</a></li><li><a class="nounderline abstract_t">Cortese S, Asherson P, Sonuga-Barke E, et al. ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. Lancet Child Adolesc Health 2020; 4:412.</a></li><li><a class="nounderline abstract_t">Cortese S, Coghill D, Santosh P, et al. Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group. Lancet Child Adolesc Health 2020; 4:e15.</a></li><li><a class="nounderline abstract_t">Wahezi DM, Lo MS, Rubinstein TB, et al. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol 2021; 73:e46.</a></li><li class="breakAll">American Academy of Pediatrics. Guidance for children and families involved with the child welfare system during the COVID-19 pandemic. services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/guidance-for-children-and-families-involved-with-the-child-welfare-system-during-the-covid-19-pandemic/ (Accessed on September 06, 2022).</li><li><a class="nounderline abstract_t">Rachlin A, Danovaro-Holliday MC, Murphy P, et al. Routine Vaccination Coverage - Worldwide, 2021. MMWR Morb Mortal Wkly Rep 2022; 71:1396.</a></li><li class="breakAll">World Health Organization. At least 80 million children under one at risk of diseases such as diphtheria, measles and polio as COVID-19 disrupts routine vaccination efforts, warn Gavi, WHO and UNICEF www.who.int/news-room/detail/22-05-2020-at-least-80-million-children-under-one-at-risk-of-diseases-such-as-diphtheria-measles-and-polio-as-covid-19-disrupts-routine-vaccination-efforts-warn-gavi-who-and-unicef (Accessed on June 17, 2020).</li><li class="breakAll">United States Centers for Disease Control and Prevention. Immunization schedules. Interim guidance to prevent mother-to-child transmission of hepatitis B virus. Available at: www.cdc.gov/vaccines/schedules/hcp/schedule-changes.html (Accessed on April 22, 2020).</li><li><a class="nounderline abstract_t">Brazendale K, Beets MW, Weaver RG, et al. Understanding differences between summer vs. school obesogenic behaviors of children: the structured days hypothesis. Int J Behav Nutr Phys Act 2017; 14:100.</a></li><li><a class="nounderline abstract_t">Lange SJ, Kompaniyets L, Freedman DS, et al. Longitudinal Trends in Body Mass Index Before and During the COVID-19 Pandemic Among Persons Aged 2-19 Years - United States, 2018-2020. MMWR Morb Mortal Wkly Rep 2021; 70:1278.</a></li><li><a class="nounderline abstract_t">Viner R, Russell S, Saulle R, et al. School Closures During Social Lockdown and Mental Health, Health Behaviors, and Well-being Among Children and Adolescents During the First COVID-19 Wave: A Systematic Review. JAMA Pediatr 2022; 176:400.</a></li><li><a class="nounderline abstract_t">Chaffee BW, Cheng J, Couch ET, et al. Adolescents' Substance Use and Physical Activity Before and During the COVID-19 Pandemic. JAMA Pediatr 2021; 175:715.</a></li><li><a class="nounderline abstract_t">Jarnig G, Jaunig J, van Poppel MNM. Association of COVID-19 Mitigation Measures With Changes in Cardiorespiratory Fitness and Body Mass Index Among Children Aged 7 to 10 Years in Austria. JAMA Netw Open 2021; 4:e2121675.</a></li><li><a class="nounderline abstract_t">Woolford SJ, Sidell M, Li X, et al. Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic. JAMA 2021; 326:1434.</a></li><li><a class="nounderline abstract_t">Nagata JM, Cortez CA, Cattle CJ, et al. Screen Time Use Among US Adolescents During the COVID-19 Pandemic: Findings From the Adolescent Brain Cognitive Development (ABCD) Study. JAMA Pediatr 2022; 176:94.</a></li><li><a class="nounderline abstract_t">Wu AJ, Aris IM, Hivert MF, et al. Association of Changes in Obesity Prevalence With the COVID-19 Pandemic in Youth in Massachusetts. JAMA Pediatr 2022; 176:198.</a></li><li><a class="nounderline abstract_t">Sum KK, Cai S, Law E, et al. COVID-19-Related Life Experiences, Outdoor Play, and Long-term Adiposity Changes Among Preschool- and School-Aged Children in Singapore 1 Year After Lockdown. JAMA Pediatr 2022; 176:280.</a></li><li><a class="nounderline abstract_t">Neville RD, Lakes KD, Hopkins WG, et al. Global Changes in Child and Adolescent Physical Activity During the COVID-19 Pandemic: A Systematic Review and Meta-analysis. JAMA Pediatr 2022; 176:886.</a></li><li><a class="nounderline abstract_t">Knapp EA, Dong Y, Dunlop AL, et al. Changes in BMI During the COVID-19 Pandemic. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Madigan S, Eirich R, Pador P, et al. Assessment of Changes in Child and Adolescent Screen Time During the COVID-19 Pandemic: A Systematic Review and Meta-analysis. JAMA Pediatr 2022; 176:1188.</a></li><li><a class="nounderline abstract_t">Wang G, Zhang Y, Zhao J, et al. Mitigate the effects of home confinement on children during the COVID-19 outbreak. Lancet 2020; 395:945.</a></li><li class="breakAll">United Nations Policy Brief: The impact of COVID-19 on children. April 2020. Available at: unsdg.un.org/resources/policy-brief-impact-covid-19-children (Accessed on April 23, 2020).</li><li><a class="nounderline abstract_t">Perrin EC, Leslie LK, Boat T. Parenting as Primary Prevention. JAMA Pediatr 2016; 170:637.</a></li><li class="breakAll">World Health Organization. Coronavirus disease (COVID-19) advice for the public: Healthy parenting. Available at: www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/healthy-parenting (Accessed on March 31, 2020).</li><li><a class="nounderline abstract_t">Cohen JS, Donnelly K, Patel SJ, et al. Firearms Injuries Involving Young Children in the United States During the COVID-19 Pandemic. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Gastineau KAB, Williams DJ, Hall M, et al. Pediatric Firearm-Related Hospital Encounters During the SARS-CoV-2 Pandemic. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Bressan S, Gallo E, Tirelli F, et al. Lockdown: more domestic accidents than COVID-19 in children. Arch Dis Child 2021; 106:e3.</a></li><li><a class="nounderline abstract_t">Lelak KA, Vohra V, Neuman MI, et al. COVID-19 and Pediatric Ingestions. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Wells JM, Rodean J, Cook L, et al. Injury-Related Pediatric Emergency Department Visits in the First Year of COVID-19. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Lãzãrescu AM, Benichi S, Blauwblomme T, et al. Abusive Head Trauma in Infants During the COVID-19 Pandemic in the Paris Metropolitan Area. JAMA Netw Open 2022; 5:e2226182.</a></li><li><a class="nounderline abstract_t">Peña PA, Jena A. Child Deaths by Gun Violence in the US During the COVID-19 Pandemic. JAMA Netw Open 2022; 5:e2225339.</a></li><li><a class="nounderline abstract_t">Iantorno SE, Swendiman RA, Bucher BT, Russell KW. Surge in Pediatric Firearm Injuries Presenting to US Children's Hospitals During the COVID-19 Pandemic. JAMA Pediatr 2023; 177:204.</a></li><li><a class="nounderline abstract_t">Pieh C, Plener PL, Probst T, et al. Assessment of Mental Health of High School Students During Social Distancing and Remote Schooling During the COVID-19 Pandemic in Austria. JAMA Netw Open 2021; 4:e2114866.</a></li><li><a class="nounderline abstract_t">Creswell C, Shum A, Pearcey S, et al. Young people's mental health during the COVID-19 pandemic. Lancet Child Adolesc Health 2021; 5:535.</a></li><li><a class="nounderline abstract_t">Mayne SL, Hannan C, Davis M, et al. COVID-19 and Adolescent Depression and Suicide Risk Screening Outcomes. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Racine N, McArthur BA, Cooke JE, et al. Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis. JAMA Pediatr 2021; 175:1142.</a></li><li><a class="nounderline abstract_t">Corrigan C, Duke G, Millar J, et al. Admissions of Children and Adolescents With Deliberate Self-harm to Intensive Care During the SARS-CoV-2 Outbreak in Australia. JAMA Netw Open 2022; 5:e2211692.</a></li><li><a class="nounderline abstract_t">Jones SE, Ethier KA, Hertz M, et al. Mental Health, Suicidality, and Connectedness Among High School Students During the COVID-19 Pandemic - Adolescent Behaviors and Experiences Survey, United States, January-June 2021. MMWR Suppl 2022; 71:16.</a></li><li><a class="nounderline abstract_t">Brener ND, Bohm MK, Jones CM, et al. Use of Tobacco Products, Alcohol, and Other Substances Among High School Students During the COVID-19 Pandemic - Adolescent Behaviors and Experiences Survey, United States, January-June 2021. MMWR Suppl 2022; 71:8.</a></li><li><a class="nounderline abstract_t">Ferrara P, Franceschini G, Corsello G, et al. Children Witnessing Domestic and Family Violence: A Widespread Occurrence during the Coronavirus Disease 2019 (COVID-19) Pandemic. J Pediatr 2021; 235:305.</a></li><li><a class="nounderline abstract_t">Bittner Gould J, Walter HJ, Bromberg J, et al. Impact of the Coronavirus Disease 2019 Pandemic on Mental Health Visits in Pediatric Primary Care. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Gutiérrez-Sacristán A, Serret-Larmande A, Hutch MR, et al. Hospitalizations Associated With Mental Health Conditions Among Adolescents in the US and France During the COVID-19 Pandemic. JAMA Netw Open 2022; 5:e2246548.</a></li><li><a class="nounderline abstract_t">Hartman-Munick SM, Lin JA, Milliren CE, et al. Association of the COVID-19 Pandemic With Adolescent and Young Adult Eating Disorder Care Volume. JAMA Pediatr 2022; 176:1225.</a></li><li><a class="nounderline abstract_t">Schnitzer PG, Dykstra H, Collier A. The COVID-19 Pandemic and Youth Suicide: 2020-2021. Pediatrics 2023; 151.</a></li><li><a class="nounderline abstract_t">Bridge JA, Ruch DA, Sheftall AH, et al. Youth Suicide During the First Year of the COVID-19 Pandemic. Pediatrics 2023; 151.</a></li><li><a class="nounderline abstract_t">Khan JR, Hu N, Lin PI, et al. COVID-19 and Pediatric Mental Health Hospitalizations. Pediatrics 2023; 151.</a></li><li><a class="nounderline abstract_t">Yard E, Radhakrishnan L, Ballesteros MF, et al. Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12-25 Years Before and During the COVID-19 Pandemic - United States, January 2019-May 2021. MMWR Morb Mortal Wkly Rep 2021; 70:888.</a></li><li><a class="nounderline abstract_t">Anderson KN, Swedo EA, Trinh E, et al. Adverse Childhood Experiences During the COVID-19 Pandemic and Associations with Poor Mental Health and Suicidal Behaviors Among High School Students - Adolescent Behaviors and Experiences Survey, United States, January-June 2021. MMWR Morb Mortal Wkly Rep 2022; 71:1301.</a></li><li><a class="nounderline abstract_t">Cluver L, Lachman JM, Sherr L, et al. Parenting in a time of COVID-19. Lancet 2020; 395:e64.</a></li><li><a class="nounderline abstract_t">Humphreys KL, Myint MT, Zeanah CH. Increased Risk for Family Violence During the COVID-19 Pandemic. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Sidpra J, Abomeli D, Hameed B, et al. Rise in the incidence of abusive head trauma during the COVID-19 pandemic. Arch Dis Child 2021; 106:e14.</a></li><li><a class="nounderline abstract_t">Bhopal S, Buckland A, McCrone R, et al. Who has been missed? Dramatic decrease in numbers of children seen for child protection assessments during the pandemic. Arch Dis Child 2021; 106:e6.</a></li><li><a class="nounderline abstract_t">Silliman Cohen RI, Bosk EA. Vulnerable Youth and the COVID-19 Pandemic. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Nearchou F, Flinn C, Niland R, et al. Exploring the Impact of COVID-19 on Mental Health Outcomes in Children and Adolescents: A Systematic Review. Int J Environ Res Public Health 2020; 17.</a></li><li><a class="nounderline abstract_t">Hillis S, N'konzi JN, Msemburi W, et al. Orphanhood and Caregiver Loss Among Children Based on New Global Excess COVID-19 Death Estimates. JAMA Pediatr 2022; 176:1145.</a></li><li class="breakAll">Children: The hidden pandemic 2021 - A joint report of COVID-19-associated orphanhood and a strategy for action. https://stacks.cdc.gov/view/cdc/108199 (Accessed on October 19, 2021).</li><li><a class="nounderline abstract_t">Forkey H, Szilagyi M, Kelly ET, et al. Trauma-Informed Care. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Slomski A. Thousands of US Youths Cope With the Trauma of Losing Parents to COVID-19. JAMA 2021; 326:2117.</a></li><li><a class="nounderline abstract_t">Lam-Hine T, McCurdy SA, Santora L, et al. Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School - Marin County, California, May-June 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1214.</a></li><li><a class="nounderline abstract_t">Jehn M, McCullough JM, Dale AP, et al. Association Between K-12 School Mask Policies and School-Associated COVID-19 Outbreaks - Maricopa and Pima Counties, Arizona, July-August 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1372.</a></li><li><a class="nounderline abstract_t">Budzyn SE, Panaggio MJ, Parks SE, et al. Pediatric COVID-19 Cases in Counties With and Without School Mask Requirements - United States, July 1-September 4, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1377.</a></li><li><a class="nounderline abstract_t">Thakkar PV, Zimmerman KO, Brookhart MA, et al. COVID-19 Incidence Among Sixth Through Twelfth Grade Students by Vaccination Status. Pediatrics 2022; 149.</a></li><li><a class="nounderline abstract_t">Cowger TL, Murray EJ, Clarke J, et al. Lifting Universal Masking in Schools - Covid-19 Incidence among Students and Staff. N Engl J Med 2022; 387:1935.</a></li><li><a class="nounderline abstract_t">Gold JAW, Gettings JR, Kimball A, et al. Clusters of SARS-CoV-2 Infection Among Elementary School Educators and Students in One School District - Georgia, December 2020-January 2021. MMWR Morb Mortal Wkly Rep 2021; 70:289.</a></li><li><a class="nounderline abstract_t">Vlachos J, Hertegård E, B Svaleryd H. The effects of school closures on SARS-CoV-2 among parents and teachers. Proc Natl Acad Sci U S A 2021; 118.</a></li><li><a class="nounderline abstract_t">Gettings JR, Gold JAW, Kimball A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in a Georgia School District-United States, December 2020-January 2021. Clin Infect Dis 2022; 74:319.</a></li><li><a class="nounderline abstract_t">Aizawa Y, Shobugawa Y, Tomiyama N, et al. Coronavirus Disease 2019 Cluster Originating in a Primary School Teachers' Room in Japan. Pediatr Infect Dis J 2021; 40:e418.</a></li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19. COVID-19 interim guidance. COVID-19 Guidance for safe schools and promotion of in-person learning. services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-planning-considerations-return-to-in-person-education-in-schools/ (Accessed on September 14, 2022).</li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19. Clinical Guidance. COVID-19 and Safe Transportation in Motor Vehicles. services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-and-safe-transportation-in-motor-vehicles/ (Accessed on August 11, 2021).</li><li class="breakAll">American Academy of Pediatrics. Critical Updates on COVID-19. Clinical Guidance. Guidance related to early care and education/child care during COVID-19. services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/guidance-related-to-childcare-during-covid-19/ (Accessed on September 01, 2021).</li><li class="breakAll">United States Centers for Disease Control and Prevention. COVID-19. Operational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe In-Person Learning https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-guidance.html (Accessed on October 06, 2022).</li><li class="breakAll">Reopening K-12 Schools During the COVID-19 Pandemic Prioritizing Health, Equity, and Communities (2020). Consensus Study Report. The National Academies Press, Washington, DC, 2020. Available at: www.nap.edu/catalog/25858/reopening-k-12-schools-during-the-covid-19-pandemic-prioritizing (Accessed on August 10, 2020).</li><li><a class="nounderline abstract_t">Orscheln RC, Newland JG, Rosen DA. Practical School Algorithms for Symptomatic or SARS-CoV-2-Exposed Students Are Essential for Returning Children to In-Person Learning. J Pediatr 2021; 229:275.</a></li><li class="breakAll">World Health Organization. Considerations for school-related public health measures in the context of COVID-19. September 14, 2020. www.who.int/publications/i/item/considerations-for-school-related-public-health-measures-in-the-context-of-covid-19 (Accessed on September 14, 2020).</li><li class="breakAll">CDC COVID-19 Science brief: Transmission of SARS-CoV-2 in K-12 schools and early care and education programs -- updated https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/transmission_k_12_schools.html (Accessed on December 29, 2021).</li><li><a class="nounderline abstract_t">Sharfstein JM, Morphew CC. The Urgency and Challenge of Opening K-12 Schools in the Fall of 2020. JAMA 2020; 324:133.</a></li><li><a class="nounderline abstract_t">Lessler J, Grabowski MK, Grantz KH, et al. Household COVID-19 risk and in-person schooling. Science 2021; 372:1092.</a></li><li><a class="nounderline abstract_t">Rubin D, Eisen M, Collins S, et al. SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program - Philadelphia County, Pennsylvania, March 21-April 23, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1040.</a></li><li><a class="nounderline abstract_t">Bose KS, Sarma RH. Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution. Biochem Biophys Res Commun 1975; 66:1173.</a></li><li><a class="nounderline abstract_t">Gaffney AW, Himmelstein D, Woolhandler S. Risk for Severe COVID-19 Illness Among Teachers and Adults Living With School-Aged Children. Ann Intern Med 2020; 173:765.</a></li><li><a class="nounderline abstract_t">Sholas MG, Apkon SD, Houtrow AJ. Children With Disabilities Must Be More Than an Afterthought in School Reopening. JAMA Pediatr 2021; 175:423.</a></li><li><a class="nounderline abstract_t">Honein MA, Barrios LC, Brooks JT. Data and Policy to Guide Opening Schools Safely to Limit the Spread of SARS-CoV-2 Infection. JAMA 2021; 325:823.</a></li><li><a class="nounderline abstract_t">Schreiber S, Faude O, Gärtner B, et al. Risk of SARS-CoV-2 transmission from on-field player contacts in amateur, youth and professional football (soccer). Br J Sports Med 2022; 56:158.</a></li><li><a class="nounderline abstract_t">Lendacki FR, Teran RA, Gretsch S, et al. COVID-19 Outbreak Among Attendees of an Exercise Facility - Chicago, Illinois, August-September 2020. MMWR Morb Mortal Wkly Rep 2021; 70:321.</a></li><li><a class="nounderline abstract_t">Groves LM, Usagawa L, Elm J, et al. Community Transmission of SARS-CoV-2 at Three Fitness Facilities - Hawaii, June-July 2020. MMWR Morb Mortal Wkly Rep 2021; 70:316.</a></li><li><a class="nounderline abstract_t">Atherstone C, Siegel M, Schmitt-Matzen E, et al. SARS-CoV-2 Transmission Associated with High School Wrestling Tournaments - Florida, December 2020-January 2021. MMWR Morb Mortal Wkly Rep 2021; 70:141.</a></li><li><a class="nounderline abstract_t">Siegel M, Kloppenburg B, Woerle S, et al. Notes from the Field: SARS-CoV-2 Transmission Associated with High School Football Team Members - Florida, September-October 2020. MMWR Morb Mortal Wkly Rep 2021; 70:402.</a></li><li><a class="nounderline abstract_t">Dougherty K, Mannell M, Naqvi O, et al. SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility - Oklahoma, April-May 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1004.</a></li><li><a class="nounderline abstract_t">Krug A, Appleby R, Pizzini R, Høeg TB. Youth ice hockey COVID-19 protocols and prevention of sport-related transmission. Br J Sports Med 2022; 56:29.</a></li></ol></div><div id="topicVersionRevision">Topic 128389 Version 150.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32918548" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32918548" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32918548" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32918548" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32918548" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32184201" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34352112" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk of SARS-CoV-2 Infection and COVID-19 Severity Associated With Exposure to Nonsteroidal Anti-Inflammatory Drugs: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32367746" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32367746" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32367746" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32367746" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32367746" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32367746" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32411815" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The severity of COVID-19 in children on immunosuppressive medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32235161" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094380" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Infection in solid-organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117944" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Infection in Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117944" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Infection in Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32472675" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Clinical Outcomes of Coronavirus Disease 2019 With Evidence-based Supportive Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32329974" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mild or Moderate Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36624396" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Community-onset bacterial coinfection in children critically ill with SARS-cov-2 infection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33174388" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35579732" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33895804" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33931403" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prevalence of thrombotic complications in children with SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35192051" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Potentially effective drugs for the treatment of COVID-19 or MIS-C in children: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32398330" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A Call for Pediatric COVID-19 Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32275812" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Compassionate Use of Remdesivir for Patients with Severe Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32187464" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33264556" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32020029" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28659436" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32054787" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32054787" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31774950" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31774950" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32445440" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Remdesivir for the Treatment of Covid-19 - Final Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33760094" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34534511" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34251904" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Update Alert: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34596223" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34606312" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Update Alert 2: Remdesivir for Adults With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35226522" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35286839" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Correction: Remdesivir for Adults With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35512728" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34350582" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Remdesivir for the treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36109390" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Guidelines for the prevention and management of children and adolescents with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36109390" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Guidelines for the prevention and management of children and adolescents with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36109390" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Guidelines for the prevention and management of children and adolescents with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32459919" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33883243" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Compassionate Use of Remdesivir in Children With Severe COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34173663" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33483798" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34285169" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sinus Bradycardia in Children Treated With Remdesivir for COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34591799" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Remdesivir, Sinus Bradycardia and Therapeutic Drug Monitoring in Children With Severe COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34591799" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Remdesivir, Sinus Bradycardia and Therapeutic Drug Monitoring in Children With Severe COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35727290" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35727290" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33306283" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34480861" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35908569" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031652" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085507" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32706953" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33493009" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Reported Adverse Drug Reactions Associated With the Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860962" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282022" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282022" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282022" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031764" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32808988" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876694" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32887691" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A living WHO guideline on drugs for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36634963" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Update to living WHO guideline on drugs for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36634963" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Update to living WHO guideline on drugs for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35258575" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35258575" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32678530" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Dexamethasone in Hospitalized Patients with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876689" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876695" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32876697" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396514" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Systemic corticosteroids for the treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396514" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Systemic corticosteroids for the treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34396514" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Systemic corticosteroids for the treatment of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36638396" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32651997" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32604407" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350002" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25030060" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32648959" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32732190" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Drug treatments for covid-19: living systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33334735" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Update to living systematic review on drug treatments for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33789885" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Update to living systematic review on drug treatments for covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33635310" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33967228" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35062755" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Efficacy of High-Dose Polyclonal Intravenous Immunoglobulin in COVID-19: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194128" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A randomized, controlled trial of vitamin A in children with severe measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194128" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A randomized, controlled trial of vitamin A in children with severe measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194128" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A randomized, controlled trial of vitamin A in children with severe measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194128" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : A randomized, controlled trial of vitamin A in children with severe measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2194128" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A randomized, controlled trial of vitamin A in children with severe measles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107571" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107571" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107571" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107571" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107571" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107571" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35107571" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36476720" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36476720" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35172054" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35878897" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36016328" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36126225" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36476522" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36476522" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36476522" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36476522" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36476522" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36476522" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36191676" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Efficacy and safety of Paxlovid for COVID-19:a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36301549" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36810665" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated Controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34937145" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34937145" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880651" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595634" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36215226" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36215222" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213507" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Covid-19: a remote assessment in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213507" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Covid-19: a remote assessment in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34269813" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33676597" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33031488" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36070710" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34318930" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Ivermectin for preventing and treating COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633838" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633838" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633838" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633838" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633838" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35025851" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Risk for Newly Diagnosed Diabetes&gt;30 Days After SARS-CoV-2 Infection Among Persons Aged&lt;18 Years - United States, March 1, 2020-June 28, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34045208" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : New-onset type 1 diabetes in Finnish children during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35119459" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35072727" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32816997" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : New-Onset Type 1 Diabetes in Children During COVID-19: Multicenter Regional Findings in the U.K.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35985535" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The Coronavirus Disease 2019 Pandemic is Associated with a Substantial Rise in Frequency and Severity of Presentation of Youth-Onset Type 2 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36149658" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Association of SARS-CoV-2 Infection With New-Onset Type 1 Diabetes Among Pediatric Patients From 2020 to 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35930271" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : SARS-CoV-2 Infections and Presymptomatic Type 1 Diabetes Autoimmunity in Children and Adolescents From Colorado, USA, and Bavaria, Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35930271" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : SARS-CoV-2 Infections and Presymptomatic Type 1 Diabetes Autoimmunity in Children and Adolescents From Colorado, USA, and Bavaria, Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34262190" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Long COVID and kids: scientists race to find answers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35143771" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35143770" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35213866" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : The Challenge of Studying Long COVID: An Updated Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36504922" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Natural course of health and well-being in non-hospitalised children and young people after testing for SARS-CoV-2: a prospective follow-up study over 12 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36504922" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Natural course of health and well-being in non-hospitalised children and young people after testing for SARS-CoV-2: a prospective follow-up study over 12 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36504922" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Natural course of health and well-being in non-hospitalised children and young people after testing for SARS-CoV-2: a prospective follow-up study over 12 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35980866" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34462339" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Telehealth: Improving Access to and Quality of Pediatric Health Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34462339" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Telehealth: Improving Access to and Quality of Pediatric Health Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34462339" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Telehealth: Improving Access to and Quality of Pediatric Health Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301434" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32790662" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Serious Adverse Health Events, Including Death, Associated with Ingesting Alcohol-Based Hand Sanitizers Containing Methanol - Arizona and New Mexico, May-June 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32790662" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Serious Adverse Health Events, Including Death, Associated with Ingesting Alcohol-Based Hand Sanitizers Containing Methanol - Arizona and New Mexico, May-June 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33475712" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Pediatric Eye Injuries by Hydroalcoholic Gel in the Context of the Coronavirus Disease 2019 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33475717" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Hand Sanitizer-Induced Ocular Injury: A COVID-19 Hazard in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32923696" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Hand sanitizer associated ocular chemical injury: A mini-review on its rise under COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32923696" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Hand sanitizer associated ocular chemical injury: A mini-review on its rise under COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32923696" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Hand sanitizer associated ocular chemical injury: A mini-review on its rise under COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32923696" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Hand sanitizer associated ocular chemical injury: A mini-review on its rise under COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32492293" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33284679" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33289973" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33289973" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33289973" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35199167" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Priorities for Safer In-Person School for Children With Medical Complexity During COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32311314" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32405517" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114365" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114365" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327156" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Routine Vaccination Coverage - Worldwide, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327156" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Routine Vaccination Coverage - Worldwide, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36327156" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Routine Vaccination Coverage - Worldwide, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28747186" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Understanding differences between summer vs. school obesogenic behaviors of children: the structured days hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34529635" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Longitudinal Trends in Body Mass Index Before and During the COVID-19 Pandemic Among Persons Aged 2-19 Years - United States, 2018-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35040870" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : School Closures During Social Lockdown and Mental Health, Health Behaviors, and Well-being Among Children and Adolescents During the First COVID-19 Wave: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33938922" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Adolescents' Substance Use and Physical Activity Before and During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34436611" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Association of COVID-19 Mitigation Measures With Changes in Cardiorespiratory Fitness and Body Mass Index Among Children Aged 7 to 10 Years in Austria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34448817" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Changes in Body Mass Index Among Children and Adolescents During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34724543" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Screen Time Use Among US Adolescents During the COVID-19 Pandemic: Findings From the Adolescent Brain Cognitive Development (ABCD) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34901998" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Association of Changes in Obesity Prevalence With the COVID-19 Pandemic in Youth in Massachusetts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35072692" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : COVID-19-Related Life Experiences, Outdoor Play, and Long-term Adiposity Changes Among Preschool- and School-Aged Children in Singapore 1 Year After Lockdown.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35816330" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Global Changes in Child and Adolescent Physical Activity During the COVID-19 Pandemic: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35768891" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Changes in BMI During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36342702" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Assessment of Changes in Child and Adolescent Screen Time During the COVID-19 Pandemic: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145186" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Mitigate the effects of home confinement on children during the COVID-19 outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145186" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Mitigate the effects of home confinement on children during the COVID-19 outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27182902" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Parenting as Primary Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27182902" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Parenting as Primary Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33850026" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Firearms Injuries Involving Young Children in the United States During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33980696" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : Pediatric Firearm-Related Hospital Encounters During the SARS-CoV-2 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32487724" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : Lockdown: more domestic accidents than COVID-19 in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33906928" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : COVID-19 and Pediatric Ingestions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35836331" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Injury-Related Pediatric Emergency Department Visits in the First Year of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36040743" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : Abusive Head Trauma in Infants During the COVID-19 Pandemic in the Paris Metropolitan Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35925607" id="rid224" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>225 : Child Deaths by Gun Violence in the US During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36534391" id="rid225" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>226 : Surge in Pediatric Firearm Injuries Presenting to US Children's Hospitals During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34181016" id="rid226" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>227 : Assessment of Mental Health of High School Students During Social Distancing and Remote Schooling During the COVID-19 Pandemic in Austria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34174991" id="rid227" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>228 : Young people's mental health during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34140393" id="rid228" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>229 : COVID-19 and Adolescent Depression and Suicide Risk Screening Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34369987" id="rid229" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>230 : Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35544133" id="rid230" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>231 : Admissions of Children and Adolescents With Deliberate Self-harm to Intensive Care During the SARS-CoV-2 Outbreak in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35358165" id="rid231" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>232 : Mental Health, Suicidality, and Connectedness Among High School Students During the COVID-19 Pandemic - Adolescent Behaviors and Experiences Survey, United States, January-June 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35358166" id="rid232" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>233 : Use of Tobacco Products, Alcohol, and Other Substances Among High School Students During the COVID-19 Pandemic - Adolescent Behaviors and Experiences Survey, United States, January-June 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33964263" id="rid233" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>234 : Children Witnessing Domestic and Family Violence: A Widespread Occurrence during the Coronavirus Disease 2019 (COVID-19) Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36330753" id="rid234" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>235 : Impact of the Coronavirus Disease 2019 Pandemic on Mental Health Visits in Pediatric Primary Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36512353" id="rid235" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>236 : Hospitalizations Associated With Mental Health Conditions Among Adolescents in the US and France During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36342721" id="rid236" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>237 : Association of the COVID-19 Pandemic With Adolescent and Young Adult Eating Disorder Care Volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36789553" id="rid237" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>238 : The COVID-19 Pandemic and Youth Suicide: 2020-2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36789551" id="rid238" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>239 : Youth Suicide During the First Year of the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37057479" id="rid239" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>240 : COVID-19 and Pediatric Mental Health Hospitalizations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34138833" id="rid240" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>241 : Emergency Department Visits for Suspected Suicide Attempts Among Persons Aged 12-25 Years Before and During the COVID-19 Pandemic - United States, January 2019-May 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36227769" id="rid241" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>242 : Adverse Childhood Experiences During the COVID-19 Pandemic and Associations with Poor Mental Health and Suicidal Behaviors Among High School Students - Adolescent Behaviors and Experiences Survey, United States, January-June 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32220657" id="rid242" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>243 : Parenting in a time of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317306" id="rid243" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>244 : Increased Risk for Family Violence During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32616522" id="rid244" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>245 : Rise in the incidence of abusive head trauma during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32554510" id="rid245" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>246 : Who has been missed? Dramatic decrease in numbers of children seen for child protection assessments during the pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345686" id="rid246" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>247 : Vulnerable Youth and the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33207689" id="rid247" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>248 : Exploring the Impact of COVID-19 on Mental Health Outcomes in Children and Adolescents: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36066897" id="rid248" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>249 : Orphanhood and Caregiver Loss Among Children Based on New Global Excess COVID-19 Death Estimates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36066897" id="rid249" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>250 : Orphanhood and Caregiver Loss Among Children Based on New Global Excess COVID-19 Death Estimates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34312292" id="rid250" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>251 : Trauma-Informed Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34787636" id="rid251" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>252 : Thousands of US Youths Cope With the Trauma of Losing Parents to COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34473683" id="rid252" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>253 : Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School - Marin County, California, May-June 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34591830" id="rid253" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>254 : Association Between K-12 School Mask Policies and School-Associated COVID-19 Outbreaks - Maricopa and Pima Counties, Arizona, July-August 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34591829" id="rid254" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>255 : Pediatric COVID-19 Cases in Counties With and Without School Mask Requirements - United States, July 1-September 4, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35190835" id="rid255" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>256 : COVID-19 Incidence Among Sixth Through Twelfth Grade Students by Vaccination Status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36351262" id="rid256" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>257 : Lifting Universal Masking in Schools - Covid-19 Incidence among Students and Staff.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33630823" id="rid257" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>258 : Clusters of SARS-CoV-2 Infection Among Elementary School Educators and Students in One School District - Georgia, December 2020-January 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33574041" id="rid258" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>259 : The effects of school closures on SARS-CoV-2 among parents and teachers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33864375" id="rid259" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>260 : Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in a Georgia School District-United States, December 2020-January 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34561385" id="rid260" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>261 : Coronavirus Disease 2019 Cluster Originating in a Primary School Teachers' Room in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34561385" id="rid261" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>262 : Coronavirus Disease 2019 Cluster Originating in a Primary School Teachers' Room in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34561385" id="rid262" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>263 : Coronavirus Disease 2019 Cluster Originating in a Primary School Teachers' Room in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34561385" id="rid263" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>264 : Coronavirus Disease 2019 Cluster Originating in a Primary School Teachers' Room in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34561385" id="rid264" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>265 : Coronavirus Disease 2019 Cluster Originating in a Primary School Teachers' Room in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34561385" id="rid265" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>266 : Coronavirus Disease 2019 Cluster Originating in a Primary School Teachers' Room in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32980377" id="rid266" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>267 : Practical School Algorithms for Symptomatic or SARS-CoV-2-Exposed Students Are Essential for Returning Children to In-Person Learning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32980377" id="rid267" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>268 : Practical School Algorithms for Symptomatic or SARS-CoV-2-Exposed Students Are Essential for Returning Children to In-Person Learning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32980377" id="rid268" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>269 : Practical School Algorithms for Symptomatic or SARS-CoV-2-Exposed Students Are Essential for Returning Children to In-Person Learning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32478827" id="rid269" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>270 : The Urgency and Challenge of Opening K-12 Schools in the Fall of 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33927057" id="rid270" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>271 : Household COVID-19 risk and in-person schooling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34324479" id="rid271" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>272 : SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program - Philadelphia County, Pennsylvania, March 21-April 23, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2" id="rid272" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>273 : Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822221" id="rid273" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>274 : Risk for Severe COVID-19 Illness Among Teachers and Adults Living With School-Aged Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33393975" id="rid274" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>275 : Children With Disabilities Must Be More Than an Afterthought in School Reopening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33497433" id="rid275" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>276 : Data and Policy to Guide Opening Schools Safely to Limit the Spread of SARS-CoV-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34663570" id="rid276" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>277 : Risk of SARS-CoV-2 transmission from on-field player contacts in amateur, youth and professional football (soccer).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661859" id="rid277" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>278 : COVID-19 Outbreak Among Attendees of an Exercise Facility - Chicago, Illinois, August-September 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33661861" id="rid278" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>279 : Community Transmission of SARS-CoV-2 at Three Fitness Facilities - Hawaii, June-July 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33507895" id="rid279" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>280 : SARS-CoV-2 Transmission Associated with High School Wrestling Tournaments - Florida, December 2020-January 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735163" id="rid280" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>281 : Notes from the Field: SARS-CoV-2 Transmission Associated with High School Football Team Members - Florida, September-October 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34264910" id="rid281" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>282 : SARS-CoV-2 B.1.617.2 (Delta) Variant COVID-19 Outbreak Associated with a Gymnastics Facility - Oklahoma, April-May 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34413053" id="rid282" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>283 : Youth ice hockey COVID-19 protocols and prevention of sport-related transmission.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
